生物学的精神医学研究室

英文論文

　 　 題名 著者 誌名 巻（号）：頁-頁, 年
2024 1 Longitudinal reduction in brain volume in patients with schizophrenia and its association with cognitive function. Yamazaki, R.Matsumoto, J.Ito, S.Nemoto, K.Fukunaga, M.Hashimoto, N.Kodaka, F.Takano, H.Hasegawa, N.Yasuda, Y.Fujimoto, M.Yamamori, H.Watanabe, Y.Miura, K.Hashimoto, R. Neuropsychopharmacology reports, 44(1)  206-215, 2024.03
2 Association between copy number variations in parkin (PRKN) and schizophrenia and autism spectrum disorder: A case-control study. Lo, T.Kushima, I.Kimura, H.Aleksic, B.Okada, T.Kato, H.Inada, T.Nawa, Y.Torii, Y.Yamamoto, M.Kimura, R.Funabiki, Y.Kosaka, H.Numata, S.Kasai, K.Sasaki, T.Yokoyama, S.Munesue, T.Hashimoto, R.Yasuda, Y.Fujimoto, M.Usami, M.Itokawa, M.Arai, M.Ohi, K.Someya, T.Watanabe, Y.Egawa, J.Takahashi, T.Suzuki, M.Yamasue, H.Iwata, N.Ikeda, M.Ozaki, N. Neuropsychopharmacology reports, 44(1)  42-50,  2024.03
3 Visual salience is affected in participants with schizophrenia during free-viewing. Yoshida, M.Miura, K.Fujimoto, M.Yamamori, H.Yasuda, Y.Iwase, M.Hashimoto, R. Neuropsychopharmacology reports, 44(1)  42-50,  2024.03
4 Gaze behaviors during free viewing revealed differences in visual salience processing across four major psychiatric disorders: a mega-analysis study of 1012 individuals K.Miura，M.Yoshida，K.Morita，M.Fujimoto，Y.Yasuda，H.Yamamori，J. Takahashi，S.Miyata，K.Okazaki，J.Matsumoto，A.Toyomaki，M.Makinodan， N.Hashimoto，T.Onitsuka，K.Kasai，N.Ozaki，R.Hashimoto Molecular Psychiatry，2024.10.11，https://doi.org/10.1038/s41380-024-02773-5
5 Copy number variations in RNF216 and postsynaptic membrane-associated genes are associated with bipolar disorder: a case-control study in the Japanese population. M Nakatochi,I Kushima,B Aleksic,H Kimura,H Kato,T Inada,Y Torii,N Takahashi, M Yamamoto,K Iwamoto,Y Nawa,S Iritani,N Iwata,T Saito, K Ninomiya, T Okochi, R Hashimoto,H Yamamori,Y Yasuda, M Fujimoto, K Miura, K Ohi, T Shioiri, K Kitaichi, M Itokawa, M Arai, M Miyashita, K Toriumi, T Takahashi, M Suzuki, T A Kato, S Kanba, H Horikawa, K Kasai, T Ikegame, S Jinde, T Kato, C Kakiuchi, B Yamagata, S Nio,Y Kunii, H Yabe, Y Okamura, S Tadaka, U Fumihiko, T Obara, Y Yamamoto, Y Arioka, D Mori, M Ikeda, N Ozaki Psychiatry and clinical neurosciences 2024.10.15
2023 1 Subcortical volumetric alterations in four major psychiatric disorders: A mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification. Okada, N.Fukunaga, M.Miura, K.Nemoto, K.Matsumoto, J.Hashimoto, N.Kiyota, M.Morita, K.Koshiyama, D.Ohi, K.Takahashi, T.Koeda, M.Yamamori, H.Fujimoto, M.Yasuda, Y.Hasegawa, N.Narita, H.Yokoyama, S.Mishima, R.Kawashima, T.Kobayashi, Y.Sasabayashi, D.Harada, K.Yamamoto, M.Hirano, Y.Itahashi, T.Nakataki, M.Hashimoto, R.Tha, K.Koike, S.Matsubara, T.Okada, G.van Erp, T.Jahanshad, N.Yoshimura, R.Abe, O.Onitsuka, T.Watanabe, Y.Matsuo, K.Yamasue, H.Okamoto, Y.Suzuki, M.Turner, J.Thompson, P.Ozaki, N.Kasai, K.Hashimoto, R. Molecular Psychiatry, 28(12) 5206-5216, 2023.12
2 Better adherence to guidelines among psychiatrists providing pharmacological therapy is associated with longer work hours in patients with schizophrenia. Ito, S.Ohi, K.Yasuda, Y.Fujimoto, M.Yamamori, H.Matsumoto, J.Fukumoto, K.Kodaka, F.Hasegawa, N.Ishimaru, K.Miura, K.Yasui-Furukori, N.Hashimoto, R. Schizophrenia (Heidelberg, Germany), 9(1) 78-78, 2023.11
3 Cerebral cortical structural alteration patterns across four major psychiatric disorders in 5549 individuals. Matsumoto, J.Fukunaga, M.Miura, K.Nemoto, K.Okada, N.Hashimoto, N.Morita, K.Koshiyama, D.Ohi, K.Takahashi, T.Koeda, M.Yamamori, H.Fujimoto, M.Yasuda, Y.Ito, S.Yamazaki, R.Hasegawa, N.Narita, H.Yokoyama, S.Mishima, R.Miyata, J.Kobayashi, Y.Sasabayashi, D.Harada, K.Yamamoto, M.Hirano, Y.Itahashi, T.Nakataki, M.Hashimoto, R. I.Tha, K. K.Koike, S.Matsubara, T.Okada, G.Yoshimura, R.Abe, O.van Erp, T. G. M.Turner, J. A.Jahanshad, N.Thompson, P. M.Onitsuka, T.Watanabe, Y.Matsuo, K.Yamasue, H.Okamoto, Y.Suzuki, M.Ozaki, N.Kasai, K.Hashimoto, R. Molecular psychiatry, 2023.11
4 Association Study Between White Matter Microstructure and Intelligence Decline in Schizophrenia. Matsumoto J, Miura K, Fukunaga M, Nemoto K, Koshiyama D, Okada N, Morita K, Yamamori H, Yasuda Y, Fujimoto M, Ito S, Hasegawa N, Watanabe Y, Kasai K, Hashimoto R. Clinical EEG and neuroscience,　54(6) 567-573, 2021.12(Epub), 2023.11(published).
5 Longitudinal characteristics of insight and clinical factors in patients with schizophrenia. Sakai, Y.Ito, S.Matsumoto, J.Yasuda, Y.Yamamori, H.Fujimoto, M.Hasegawa, N.Ishimaru, K.Miura, K.Hashimoto, R. Neuropsychopharmacology reports,　43(3) 373-381, 2023.09,
6 Relationships between Adherence to Guideline Recommendations for Pharmacological Therapy among Clinicians and Psychotic Symptoms in Patients with Schizophrenia. Kodaka, F.Ohi, K.Yasuda, Y.Fujimoto, M.Yamamori, H.Hasegawa, N.Ito, S.Fukumoto, K.Matsumoto, J.Miura, K.Yasui-Furukori, N.Hashimoto, R. The international journal of neuropsychopharmacology,　26(8) 557-565, 2023.8
7 Discrimination in the clinical diagnosis between patients with schizophrenia and healthy controls using eye movement and cognitive functions. Okazaki, K. Miura, K. Matsumoto, J.Hasegawa, N.Fujimoto, M.Yamamori,H.Yasuda, Y.Makinodan, M.Hashimoto, R. Psychiatry and clinical neurosciences, 77(7) 393-400, 2023.7
2022 1 Neurocognitive features, personality traits, and social function in patients with schizophrenia with a history of violence. Kashiwagi H, Matsumoto J, Miura K, Takeda K, Yamada Y, Fujimoto M, Yasuda Y, Yamamori H, Ikeda M, Hirabayashi N, Hashimoto R. Journal of psychiatric research, 147:50-58,2022.3
2 Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. Ogasawara, K.Numata, S.Hasegawa, N.Nakataki, M.Makinodan, M.Ohi, K.Takeshima, M.Tsuboi, T.Hashimoto, N.Onitsuka, T.Muraoka, H.Hori, H.Ichihashi, K.Inagaki, T.Yasui-Furukori, N.Hishimoto, A.Sugiyama, N.Fukumoto, K.Nagasawa, T.Matsumoto, J.Takaesu, Y.Furihata, R.Nemoto, K.Nakamura, T.Usami, M.Miura, K.Fujimoto, M.Tagata, H.Yamada, H.Komatsu, H.Ochi, S.Atake, K.Katsumoto, E.Kido, M.Kishimoto, T.Suwa, T.Yamamura, S.Iga, J. I.Iida, H.Inada, K.Watanabe, K.Hashimoto, R. Neuropsychopharmacology reports, 42(2):221-225,2022.03.10
3 Relationship between autistic traits and social functioning in healthy individuals. Demizu, Y.Matsumoto, J.Yasuda, Y.Ito, S.Miura, K.Yamamori, H.Fujimoto, M.Hasegawa, N.Ishimaru, K.Hashimoto, R Neuropsychopharmacology reports, 42(2):226-229,2022.04.01
4 A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project. Yamada, H.Motoyama, M.Hasegawa, N.Miura, K.Matsumoto, J.Ohi, K.Yasui-Furukori, N.Numata, S.Takeshima, M.Sugiyama, N.Nagasawa, T.Kubota, C.Atake, K.Tsuboi, T.Ichihashi, K.Hashimoto, N.Inagaki, T.Takaesu, Y.Iga, J. I.Hori, H.Onitsuka, T.Komatsu, H.Hishimoto, A.Fukumoto, K.Fujimoto, M.Nakamura, T.Nemoto, K.Furihata, R.Yamamura, S.Yamagata, H.Ogasawara, K.Katsumoto, E.Murata, A.Iida, H.Ochi, S.Makinodan, M.Kido, M.Kishimoto, T.Yasuda, Y.Usami, M.Suwa, T.Inada, K.Watanabe, K.Hashimoto, R. BJPsych Open, 8(3):e83, 2022.4.21
5 Cross-Disorder Analysis of Genic and Regulatory Copy Number Variations in Bipolar Disorder, Schizophrenia, and Autism Spectrum Disorder. Kushima, I.Nakatochi, M.Aleksic, B.Okada, T.Kimura, H.Kato, H.Morikawa, M.Inada, T.Ishizuka, K.Torii, Y.Nakamura, Y.Tanaka, S.Imaeda, M.Takahashi, N.Yamamoto, M.Iwamoto, K.Nawa, Y.Ogawa, N.Iritani, S.Hayashi, Y.Lo, T.Otgonbayar, G.Furuta, S.Iwata, N.Ikeda, M.Saito, T.Ninomiya, K.Okochi, T.Hashimoto, R.Yamamori, H.Yasuda, Y.Fujimoto, M.Miura, K.Itokawa, M.Arai, M.Miyashita, M.Toriumi, K.Ohi, K.Shioiri, T.Kitaichi, K.Someya, T.Watanabe, Y.Egawa, J.Takahashi, T.Suzuki, M.Sasaki, T.Tochigi, M.Nishimura, F.Yamasue, H.Kuwabara, H.Wakuda, T.Kato, T. A.Kanba, S.Horikawa, H.Usami, M.Kodaira, M.Watanabe, K.Yoshikawa, T.Toyota, T.Yokoyama, S.Munesue, T.Kimura, R.Funabiki, Y.Kosaka, H.Jung, M.Kasai, K.Ikegame, T.Jinde, S.Numata, S.Kinoshita, M.Kato, T.Kakiuchi, C.Yamakawa, K.Suzuki, T.Hashimoto, N.Ishikawa, S.Yamagata, B.Nio, S.Murai, T.Son, S.Kunii, Y.Yabe, H.Inagaki, M.Goto, Y. I.Okumura, Y.Ito, T.Arioka, Y.Mori, D.Ozaki, N. Biol Psychiatry, 92(5) 362-374, 2022.9
6 Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: A real-world nationwide study. Ochi, S.Tagata, H.Hasegawa, N.Yasui-Furukori, N.Iga, J. I.Kashiwagi, H.Kodaka, F.Komatsu, H.Tsuboi, T.Tokutani, A.Numata, S.Ichihashi, K.Onitsuka, T.Muraoka, H.Iida, H.Ohi, K.Atake, K.Kishimoto, T.Hori, H.Takaesu, Y.Takeshima, M.Usami, M.Makinodan, M.Hashimoto, N.Fujimoto, M.Furihata, R.Nagasawa, T.Yamada, H.Matsumoto, J.Miura, K.Kido, M.Hishimoto, A.Ueno, S. I.Watanabe, K.Inada, K.Hashimoto, R. Int J Neuropsychopharmacol, 25(10) 818-826, 2022.10
7 Transdiagnostic comparisons of intellectual abilities and work outcome in patients with mental disorders: multicentre study. Sumiyoshi, C.Ohi, K.Fujino, H.Yamamori, H.Fujimoto, M.Yasuda, Y.Uno, Y.Takahashi, J.Morita, K.Katsuki, A.Yamamoto, M.Okahisa, Y.Sata, A.Katsumoto, E.Koeda, M.Hirano, Y.Nakataki, M.Matsumoto, J.Miura, K.Hashimoto, N.Makinodan, M.Takahashi, T.Nemoto, K.Kishimoto, T.Suzuki, M.Sumiyoshi, T.Hashimoto, R. BJPsych Open, 8(4):e98, 1-9, 2022.06
8 Association between globus pallidus volume and positive symptoms in schizophrenia. Ito, S.Miura, K.Miyayama, M.Matsumoto, J.Fukunaga, M.Ishimaru, K.Fujimoto, M.Yasuda, Y.Watanabe, Psychiatry and clinical neurosciences, 76(11):602-603, 2022.11
2021 1 Relationship between white matter microstructure and work hours.  Matsumoto J, Fukunaga M, Miura K, Nemoto K, Koshiyama D, Okada N, Morita K, Yamamori H, Yasuda Y, Fujimoto M, Hasegawa N, Watanabe Y, Kasai K, *Hashimoto R.  Neuroscience letters. 740 135428-135428, 2021.1.
2 Prediction of lithium response using genomic data. Stone W, Nunes A, Akiyama K, Akula N, Ardau R, Aubry JM, Backlund L, Bauer M, Bellivier F, Cervantes P, Chen HC, Chillotti C, Cruceanu C, Dayer A, Degenhardt F, Del Zompo M, Forstner AJ, Frye M, Fullerton JM, Grigoroiu-Serbanescu M, Grof P, Hashimoto R,(52名中22番目) Hou L, Jiménez E, Kato T, Kelsoe J, Kittel-Schneider S, Kuo PH, Kusumi I, Lavebratt C, Manchia M, Martinsson L, Mattheisen M, McMahon FJ, Millischer V, Mitchell PB, Nöthen MM, O'Donovan C, Ozaki N, Pisanu C, Reif A, Rietschel M, Rouleau G, Rybakowski J, Schalling M, Schofield PR, Schulze TG, Severino G, Squassina A, Veeh J, Vieta E, Trappenberg T, Alda M.  Sci Rep. 11(1):1155,
2021
3 Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders.  Writing Committee for the Attention-Deficit/Hyperactivity Disorder; Autism Spectrum Disorder; Bipolar Disorder; Major Depressive Disorder; Obsessive-Compulsive Disorder; and Schizophrenia ENIGMA Working Groups, Patel Y, （208名中略）Hashimoto R,(288名中210番目) （77名中略）Paus T. J AMA Psychiatry, 78(1):
47-63, 2021
4 Platelet-Derived Growth Factor BB: A Potential Diagnostic Blood Biomarker for Differentiating Bipolar Disorder from Major Depressive Disorder.  Idemoto K, Ishima T, Niitsu T, Hata T, Yoshida S, Hattori K, Horai T, Otsuka I, Yamamori H, Toda S, Kameno Y, Ota K, Oda Y, Kimura A, Hashimoto T, Mori N, Kikuchi M, Minabe Y, Hashimoto R, Hishimoto A, Nakagome K, Iyo M, Hashimoto K. J Psychiatr Res, 134:
48-56, 2021
5  Impaired inhibition of return during free-viewing behaviour in patients with schizophrenia. Okada K, Miura K, Fujimoto M, Morita K, Yoshida M, Yamamori H, Yasuda Y, Iwase M, Shinozaki T, Fujita I, *Hashimoto R.  Scientific reports, 11(1):3237-3237, 2021.2
6 Facilitative effects of transcranial direct current stimulation on semantic memory examined by text-mining analysis in patients with Schizophrenia.  Sumiyoshi C, Narita Z, Inagawa T, Yamada Y, Sueyoshi K, Hasegawa Y, Shirama A, Hashimoto R, Sumiyoshi T.  Front Neurol, section Neurorehabilitation,
12:583027, 2021
7  Intranasal oxytocin administration ameliorates social behavioral deficits in POGZWT/Q1038R mouse model of autism spectrum disorder. Kitagawa K, Matsumura K, Baba M, Kondo M, Takemoto T, Nagayasu K, Ago Y, Seiriki K, Hayata-Takano A, Kasai A, Takuma K, Hashimoto R, Hashimoto H, Nakazawa T.   Mol Brain, 14:56,
2021
8 1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans. Sønderby IE, （54名中略）Hashimoto R (145 名中56番目), （88名中略）Andreassen OA; ENIGMA-CNV working group.  Transl Psychiatry, 11(1):182, 2021
9 Serum levels of glial cell line-derived neurotrophic factor as a biomarker for mood disorders and lithium response.  Idemoto K, Niitsu T, Hata T, Ishima T, Yoshida S, Hattori K, Horai T, Otsuka I, Yamamori H, Toda S, Kameno Y, Ota K, Oda Y, Kimura A, Hashimoto T, Mori N, Kikuchi M, Minabe Y, Hashimoto R, Hishimoto A, Nakagome K, Hashimoto K, Iyo M. Psychiatry Res. 301:113967, 2021
10 Weather sensitivity associated with quality of life in patients with fibromyalgia.  Hayashi K, Miki K, Hayashi N, Hashimoto R, Yukioka M.  BMC Rheumatol, 5(1):
14, 2021
11 Criminal victimization of people with epilepsy: Sixteen criminal judgments in Japan between 1990 and 2019. Takeda K, Yamashita S, Taniguchi G, Kuramochi I, Murakami M, Kashiwagi H, Hashimoto R, Hirabayashi N, Okada T.   Epilepsy Behav. 118:107912, 2021
12  Positive association between insight and attitudes toward medication in Japanese patients with schizophrenia: Evaluation with the Schedule for Assessment of Insight (SAI) and the Drug Attitude Inventory - 10 Questionnaire (DAI-10).  Ito S, Matsumoto J, Sakai Y, Miura K, Hasegawa N, Yamamori H, Ishimaru K, Kim Y, Hashimoto R. Psychiatry Clin Neurosci, 75(5):187-188,
2021
13  Effects of age and sex on eye movement characteristics.  Takahashi J, Miura K, Morita K, Fujimoto M, Miyata S, Okazaki K, Matsumoto J, Hasegawa N, Hirano Y, Yamamori H, Yasuda Y, Makinodan M, Kasai K, Ozaki N, Onitsuka T, Hashimoto R. Neuropsychopharmacol Rep, 41(2):152-158,
2021
14  Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Numata S, Nakataki M, Hasegawa N, Takaesu Y, Takeshima M, Onitsuka T, Nakamura T, Edagawa R, Edo H, Miura K, Matsumoto J, Yasui-Furukori N, Kishimoto T, Hori H, Tsuboi T, Yasuda Y, Furihata R, Muraoka H, Ochi S, Nagasawa T, Kyou Y, Murata A, Katsumoto E, Ohi K, Hishimoto A, Inada K, Watanabe K, Hashimoto R.  Neuropsychopharmacol Rep, 41(2):199-206,
2021
15 Association of polygenic score for major depression with response to lithium in patients with bipolar disorder.  Amare AT, （46名中略） Hashimoto R, (113名中48番目) （64名中略） Baune BT.  Mol Psychiatry,  26(6):2457-2470,
2021
16 Polygenic Risk Scores Differentiating Schizophrenia From Bipolar Disorder Are Associated With Premorbid Intelligence in Schizophrenia Patients and Healthy Subjects.  Ohi K, Nishizawa D, Sugiyama S, Takai K, Kuramitsu A, Hasegawa J, Soda M, Kitaichi K, Hashimoto R, Ikeda K, Shioiri T. Int J Neuropsychopharmaco, 24(7):562-569,
2021
17 Neural networks associated with quality of life in patients with Parkinson's disease.  Nakano T, Kajiyama Y, Revankar G, Hashimoto R, Watanabe Y, Kishima H, Ikeda M, Mihara M, Mochizuki H, Hattori N.  Parkinsonism and
Related Disorders, 89:
6-12, 2021
18  Macaque monkeys show reversed ocular following responses to two-frame-motion stimulus presented with inter-stimulus intervals.  Takemura A, Matsumoto J, Hashimoto R, Kawano K, Miura K. J Comput Neurosci, 49(3):273-282, 2021
19 Eye Movement Abnormalities in Major Depressive Disorder. Takahashi J, Hirano Y, Miura K, Morita K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Shishido E, Okazaki K, Shiino T, Nakao T, Kasai K, Hashimoto R, Onitsuka T.  Frontiers in psychiatry, 12 673443-673443, 2021.8
20 Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project.  Hashimoto N, Yasui-Furukori N, Hasegawa N, Ishikawa S, Numata S, Hori H, Iida H, Ichihashi K, Furihata R, Murata A, Tsuboi T, Takeshima M, Kyou Y, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Hishimoto A, Miura K, Matsumoto J, Ohi K, Yamada H, Inada K, Watanabe K, Shimoda K, Hashimoto R.  Asian J Psychiatr, 63:102744, 2021
21 Association of adverse childhood experiences and precuneus volume with intrusive reexperiencing in autism spectrum disorder.  Kitamura S, Makinodan M, Matsuoka K, Takahashi M, Yoshikawa H, Ishida R, Kishimoto N, Yasuno F, Yasuda Y, Hashimoto R, Miyasaka T, Kichikawa K, Kishimoto T. Autism Res, 14(9):
1886-1895,2021
22 Optimized protocol for the extraction of RNA and DNA from frozen whole blood sample stored in a single EDTA tube.  Yamagata H, Kobayashi A, Tsunedomi R, Seki T, Kobayashi M, Hagiwara K, Che C, Uchida S, Okada G, Fuchikami M, Kamishikiryo T, Iga J, Numata S, Kinoshita M, Kato TA, Hashimoto R, Nagano H, Okamoto Y, Ueno S, Ohmori T, Nakagawa S.  Sci Rep, 11(1):17075,
2021
23 HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders.  Le Clerc S, （49名中略） Hashimoto R(122名中51番目)，（71名中略）Tamouza R.  Sci Rep, 11(1):17823,
2021
24 Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia". Japanese Society of Neuropsychopharmacology.  Neuropsychopharmacol Rep, 41(3):266-324,
2021
25  Methylation Analysis in Monozygotic Twins With Treatment-Resistant Schizophrenia and Discordant Responses to Clozapine. Kikuchi M, Nakazawa T, Kinoshita M, Yamamori H, Yasuda Y, Fujimoto M, Hashimoto R, Numata S.  Frontiers in psychiatry, 12:734606-734606, 2021.9.20
26 Decreased frontotemporal connectivity in patients with parkinson's disease experiencing face pareidolia. Kajiyama Y, Hattori N, Nakano T, Revankar G.S., Otomune H, Hashimoto R, Mori E, Ikeda M, Mihara M, Mochizuki H.  npj Parkinsons Dis.
7:90, 2021
27 Multiple alterations in glutamatergic transmission and dopamine D2 receptor splicing in induced pluripotent stem cell-derived neurons from patients with familial schizophrenia.  Yamamoto K, Kuriu T, Matsumura K, Nagayasu K, Tsurusaki Y, Miyake N, Yamamori H, Yasuda Y, Fujimoto M, Fujiwara M, Baba M, Kitagawa K, Takemoto T, Gotoda-Nishimura N, Takada T, Seiriki K, Hayata-Takano A, Kasai A, Ago Y, Kida S, Takuma K, Ono F, Matsumoto N, Hashimoto R, Hashimoto H, Nakazawa T.  Transl Psychiatry, 11(1):548, 2021
28 Tumor necrosis factor-α expression aberration of M1/M2 macrophages in adult high-functioning autism spectrum disorder.  Yamauchi T, Makinodan M, Toritsuka M, Okumura K, Kayashima Y, Ishida R, Kishimoto N, Takahashi M, Komori T, Yamaguchi Y, Takada R, Yamamuro K, Kimoto S, Yasuda Y, Hashimoto R, Kishimoto T.  Autism Res. 14(11):
2330-2341, 2021
29 Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients.  Schubert KO,(42名中略） Hashimoto R(117名中44番目), （72名中略）Baune BT.  Transl Psychiatry, 29;11(1):606, 2021
30 AKR1A1 variant associated with schizophrenia causes exon skipping, leading to loss of enzymatic activity,  Iino K, Toriumi K, Agarie R, Miyashita M, Suzuki K, Horiuchi Y, Niizato K, Oshima K, Imai A, Nagase Y, Kushima I, Koike S, Ikegame T, Jinde S, Nagata E, Washizuka S, Miyata T, Takizawa S, Hashimoto R, Kasai K, Ozaki N, Itokawa M, Arai M. Front Genetics, section Neurogenomics. 12:
762999, 2021
31 Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study. Furihata R, Otsuki R, Hasegawa N, Tsuboi T, Numata S, Yasui-Furukori N, Kashiwagi H, Hori H, Ochi S, Muraoka H, Onitsuka T, Komatsu H, Takeshima M, Hishimoto A, Nagasawa T, Takaesu Y, Nakamura T, Asami T, Miura K, Matsumoto J, Ohi K, Yasuda Y, Iida H, Ogasawara K, Hashimoto N, Ichihashi K, Yamada H, Watanabe K, Inada K, *Hashimoto R.  Sleep Med、89:23-30, 2021
32 No adverse events were observed in clozapine-treated patients on extended hematologic monitoring intervals during the coronavirus pandemic in four psychiatric centers in Japan. Hata M, Fujimoto M, Kanai K, Yoshiyama K, Nakatani Y, Nakabayashi D, Maemura S, Kawata S, Hakozaki T, Nishikura S, Umemoto A, Sasada T, Iwata K, Tanaka H, Mamoto A, Toi Y, Taniguchi N, Saito M, Kimura Y, Kishimoto K, Hayami M, Ikeda M. Neuropsychopharmacology reports, 41(2):179-184, 2021.6.
33 thnicity-Dependent Effects of Schizophrenia Risk Variants of the OLIG2 Gene on OLIG2 Transcription and White Matter Integrity. Komatsu H, Takeuchi H, Kikuchi Y, Ono C, Yu Z, Iizuka K, Takano Y, Kakuto Y, Funakoshi S, Ono T, Ito J, Kunii Y, Hino M, Nagaoka A, Iwasaki Y, Yamamori H, Yasuda Y, Fujimoto M, Azechi H, Kudo N, Hashimoto R, Yabe H, Yoshida M, Saito Y, Kakita A, Fuse N, Kawashima R, Taki Y, Tomita H Schizophrenia bulletin. 46(6) 1619-1628, 2020.12.
2020 1 Unmet needs of patients with major depressive disorder - Findings from the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study. Iida H, Iga J, Hasegawa N, Yasuda Y, Yamamoto T, Miura K, Matsumoto J, Murata A, Ogasawara K, Yamada H, Hori H, Ichihashi K, Hashimoto N, Ohi K, Yasui-Furukori N, Tsuboi T, Nakamura T, Usami M, Furihata R, Takaesu Y, Iwamoto K, Sugiyama N, Kishimoto T, Tsujino N, Yamada H, Hishimoto A, Nemoto K, Atake K, Muraoka H, Katsumoto E, Oishi S, Inagaki T, Ito F, Imamura Y, Kido M, Nagasawa T, Numata S, Ochi S, Iwata M, Yamamori H, Fujita J, Onitsuka T, Yamamura S, Makinodan M, Fujimoto M, Takayanagi Y, Takezawa K, Komatsu H, Fukumoto K, Tamai S, Yamagata H, Kubota C, Horai T, Inada K, Watanabe K, Kawasaki H, Hashimoto R.  Psychiatry Clin Neurosci,74(12):667-669, 2020
2 Ethnicity-Dependent Effects of Schizophrenia Risk Variants of the OLIG2 Gene on OLIG2 Transcription and White Matter Integrity.  Komatsu H, Takeuchi H, Kikuchi Y, Ono C, Yu Z, Iizuka K, Takano Y, Kakuto Y, Funakoshi S, Ono T, Ito J, Kunii Y, Hino M, Nagaoka A, Iwasaki Y, Yamamori H, Yasuda Y, Fujimoto M, Azechi H, Kudo N, Hashimoto R, Yabe H, Yoshida M, Saito Y, Kakita A, Fuse N, Kawashima R, Taki Y, Tomita H. Schizophr Bull, 1;46(6):1619-1628, 2020
3 Promoter Activity-Based Case-Control Association Study on SLC6A4 Highlighting Hypermethylation and Altered Amygdala Volume in Male Patients With Schizophrenia.  Ikegame T, Bundo M, Okada N, Murata Y, Koike S, Sugawara H, Saito T, Ikeda M, Owada K, Fukunaga M, Yamashita F, Koshiyama D, Natsubori T, Iwashiro N, Asai T, Yoshikawa A, Nishimura F, Kawamura Y, Ishigooka J, Kakiuchi C, Sasaki T, Abe O, Hashimoto R, Iwata N, Yamasue H, Kato T, Kasai K, Iwamoto K. Schizophr Bull, 46(6):
1577-1586,2020
4 Polygenic risk scores for late smoking initiation associated with the risk of schizophrenia. Ohi K, Nishizawa D, Muto Y, Sugiyama S, Hasegawa J, Soda M, Kitaichi K, Hashimoto R, Shioiri T, Ikeda K. NPJ Schizophr,
6(1):36, 2020
5 Association between the superior longitudinal fasciculus and perceptual organization and working memory: A diffusion tensor imaging study. Koshiyama D, Fukunaga M, Okada N, Morita K, Nemoto K, Yamashita F, Yamamori H, Yasuda Y, Matsumoto J, Fujimoto M, Kudo N, Azechi H, Watanabe Y, Kasai K, Hashimoto R. Neurosci Lett,
738:135349, 2020
6 Increased Dendritic Orientation Dispersion in the Left Occipital Gyrus is Associated with Atypical Visual Processing in Adults with Autism Spectrum Disorder.  Matsuoka K, Makinodan M, Kitamura S, Takahashi M, Yoshikawa H, Yasuno F,Ishida R, Kishimoto N, Yasuda Y, Hashimoto R, Taoka T, Miyasaka T, Kichikawa K, Kishimoto T. Cereb Cortex, 30(11):
5617-5625, 2020
7 An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium. Wong TY, （36名中略）, Hashimoto R, (66名中38番目）, （26名中略）, Nickl-Jockschat T.   Psychol Med.
50(12):2034-2045.2020
8 Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project. Ichihashi K, Hori H, Hasegawa N, Yasuda Y, Yamamoto T, Tsuboi T, Iwamoto K, Kishimoto T, Horai T, Yamada H, Sugiyama N, Nakamura T, Tsujino N, Nemoto K, Oishi S, Usami M, Katsumoto E, Yamamori H, Tomita H, Suwa T, Furihata R, Inagaki T, Fujita J, Onitsuka T, Miura K, Matsumoto J, Ohi K, Matsui Y, Takaesu Y, Hashimoto N, Iga J, Ogasawara K, Yamada H, Watanabe K, Inada K, *Hashimoto R.  Neuropsychopharmacol
Rep, 40(3):281-286,
2020
9 Associations of childhood experiences with event-related potentials in adults with autism spectrum disorder. Okazaki K, Ota T, Makinodan M, Kishimoto N, Yamamuro, Ishida R, Takahashi M, Yasuda Y, Hashimoto R, Iida J, Kishimoto T. Sci Rep, 10(1):13447,
2020
10 ARHGAP10, which encodes Rho GTPase-activating protein 10, is a novel gene for schizophrenia risk. Sekiguchi M, Sobue A, Kushima I, Wang C, Arioka Y, Kato H, Kodama A, Kubo H, Ito N, Sawahata M, Hada K, Ikeda R, Shinno M, Mizukoshi C, Tsujimura K, Yoshimi A, Ishizuka K, Takasaki Y, Kimura H, Xing J, Yu Y, Yamamoto M, Okada T, Shishido E, Inada T, Nakatochi M, Takano T, Kuroda K, Amano M, Aleksic B, Yamomoto T, Sakuma T, Aida T, Tanaka K, Hashimoto R, Arai M, Ikeda M, Iwata N, Shimamura T, Nagai T, Nabeshima T, Kaibuchi K, Yamada K, Mori D, Ozaki N. Transl Psychiatry,
10(1):247, 2020
11 Investigating DNA methylation of SHATI/NAT8L promoter sites in blood of unmedicated patients with major depressive disorder. Miyanishi H, Uno K, Iwata M, Kikuchi Y, Yamamori H, Yasuda Y, Ohi K, Hashimoto R, Hattori K, Yoshida S, Goto Y, Sumiyoshi T, Nitta A. Biol Pharm Bull,
43(7):1067-1072,
2020
12 The Self-Construal Scale: a potential tool for predicting subjective well-being of individuals with autism spectrum disorder. Kaneko S, Kato T, Makinodan M, Komori T, Ishida R, Kishimoto N, Takahashi M, Yasuda Y, Hashimoto R, Iwasaka H, Tanaka A, Uchida Y, Kanba S, Kishimoto T.  Autism Res,
13(6):947-958, 2020
13 Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia. Kudo N, Yamamori H, Ishima T, Nemoto K, Yasuda Y, Fujimoto M, Azechi H, Niitsu T, Numata S, Ikeda M, Iyo M, Ohmori T, Fukunaga M, Watanabe Y, Hashimoto K, *Hashimoto R. Neuropsychopharmacol
Rep. 40(2):150-156.
2020
14 Human leukocyte antigen DRB1*04:05 and clozapine-induced agranulocytosis/granulocytopenia. Saito T, Ikeda M, Mushiroda T, Iwata N, Clozapine Pharmacogenomics Consortium of Japan (CPC-J). Aust N Z J Psychiatry.
54(5):545-546, 2020
15 Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition. Writing Committee for the ENIGMA-CNV Working Group , van der Meer D, 　(51名中略)　Hashimoto R, (132名中53番目)  (78名中略)　Andreassen OA.  JAMA Psychiatry,
77(4):420-430, 2020
16 Polygenetic Risk Scores for Major Psychiatric Disorders Among Schizophrenia Patients, Their First-Degree Relatives, and Healthy Participants.  Ohi K, Nishizawa D, Shimada T, Kataoka Y, Hasegawa J, Shioiri T, Kawasaki Y, Hashimoto R, Ikeda K. Int J
Neuropsychopharmacol
, 23(3):157-164, 2020
17 Polygenic Architecture of Human Neuroanatomical Diversity. Biton A, Traut N, Poline JB, Aribisala BS, Bastin ME, Bülow R, Cox SR, Deary IJ, Fukunaga M, Grabe HJ, Hagenaars S, Hashimoto R, Kikuchi M, Muñoz Maniega S, Nauck M, Royle NA, Teumer A, Valdés Hernández M, Völker U, Wardlaw JM, Wittfeld K, Yamamori H; Alzheimer's Disease Neuroimaging Initiative, Bourgeron T, Toro R. Cereb Cortex,
30(4):2307-2320.
 2020
18 White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individuals. Koshiyama D, Fukunaga M, Okada N, Morita K, Nemoto K, Usui K, Yamamori H, Yasuda Y, Fujimoto M, Kudo N, Azechi H, Watanabe Y, Hashimoto N, Narita H, Kusumi I, Ohi K, Shimada T, Kataoka Y, Yamamoto M, Ozaki N, Okada G, Okamoto Y, Harada K, Matsuo K, Yamasue H, Abe O, Hashimoto R, Takahashi T, Hori T, Nakataki M, Onitsuka T, Holleran L, Jahanshad N, van Erp TGM, Turner J, Donohoe G, Thompson PM, Kasai K, *Hashimoto R, COCORO. Molecular Psychiatry. 25(4):883-895, 2020
19 Differences in fractional anisotropy between the patients with schizophrenia and healthy comparison subjects. Koshiyama D, Fukunaga M, Okada N, Morita K, Nemoto K, Usui K, Yamamori H, Yasuda Y, Fujimoto M, Kudo N, Azechi H, Watanabe Y, Hashimoto N, Narita H, Kusumi I, Ohi K, Shimada T, Kataoka Y, Yamamoto M, Ozaki N, Okada G, Okamoto Y, Harada K, Matsuo K, Yamasue H, Abe O, Hashimoto R, Takahashi T, Hori T, Nakataki M, Onitsuka T, Holleran L, Jahanshad N, van Erp TGM, Turner J, Donohoe G, Thompson PM, Kasai K, *Hashimoto R, COCORO. Mol Psychiatry, 25(4):697-698, 2020
20 Comparison of eye movements in schizophrenia and autism spectrum disorder. Shiino T, Miura K, Fujimoto M, Kudo N, Yamamori H, Yasuda Y, Ikeda M, Hashimoto R. Neuropsychopharmacology reports. 40(1) 92-95,2020.03
21 Brain morphological and functional features in cognitive subgroups of schizophrenia. Yasuda Y, Okada N, Nemoto K, Fukunaga M, Yamamori H, Ohi K, Koshiyama D, Kudo N, Shiino T, Morita S, Morita K, Azechi H, Fujimoto M, Miura K, Watanabe Y, Kasai K, Hashimoto R. Psychiatry and clinical neurosciences. 74(3) 191-203.
22 Pathogenic POGZ mutation causes impaired cortical development and reversible autism-like phenotypes. Matsumura K, Seiriki K, Okada S, Nagase M, Ayabe S, Yamada I, Furuse T, Shibuya H, Yasuda Y, Yamamori H, Fujimoto M, Nagayasu K, Yamamoto K, Kitagawa K, Miura H, Gotoda-Nishimura N, Igarashi H, Hayashida M, Masayuki, Kondo M, Hasebe S, Ueshima K, Kasai A, Ago Y, Hayata-Takano A, Shintani N, Iguchi T, Sato M, Yamaguchi S, Tamura M, Wakana S, Yoshiki A, Watabe A, Okano H, Takuma K, Hashimoto R, Hashimoto H, Nakazawa T. Nature communications. 11(1) 859-859, 2020.
2019 1 Autism-associated protein kinase D2 regulates embryonic cortical neuron development Matsumura K, Baba M, Nagayasu K, Yamamoto K, Kondo M, Kitagawa K, Takemoto T, Seiriki K, Kasai A, Ago Y, Hayata-Takano A, Shintani N, Kuriu T, Iguchi T, Sato M, Takuma K, Hashimoto R, Hashimoto H Biochem Biophys
 Res Commun
（BBRC）519(3):
626-632, 2019
2 Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process? van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, Pearlson GD, Yao N, Fukunaga M, Hashimoto R et al Biol Psychiatry
85(7):e35-e39. 2019
3 A 1.5-year Longitudinal Study of Social Activity in Patients with Schizophrenia. Ohi K, Sumiyoshi C, Fujino H, Yasuda Y, Yamamori H, Fujimoto M, Sumiyoshi T, Hashimoto R Front Psychiatry,
section Schizophrenia.
10:567, 2019
4 Current Perspective: Modeling of psychiatric disorders using induced pluripotent stem cell-related technologies Nakazawa T, Hashimoto R, Takuma K, Hashimoto H J Pharmacol Sci 140(4):321-324, 2019
5 Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design Oya K, Sakuma K, Esumi S, Hashimoto Y, Hatano M, Matsuda Y, Matsui Y, Miyake N, Nomura I, Okuya M, Iwata N, Kato M, Hashimoto R, Mishima K, Watanabe N, Kishi T Neuropsychopharmacol
Rep. 39(3):241-246,
2019
6 Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity in a mouse model of 3q29 deletion syndrome Baba M, Yokoyama K, Seiriki K, Naka Y, Matsumura K, Kondo M, Yamamoto K, Hayashida M, Kasai A, Ago Y, Nagayasu K, Hayata-Takano A, Takahashi A, Yamaguchi S, Mori D, Ozaki N, Yamamoto T, Takuma K, Hashimoto R, Hashimoto H, Nakazawa T Neuropsychopharmacol
ogy 44(12):2125-2135,
2019
7 Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE) " project: a nationwide dissemination, education and evaluation study Takaesu Y, Watanabe K, Numata S, Iwata M, Kudo N, Oishi S, Takizawa T, Nemoto K, Yasuda Y, Tagata H,  Tsuboi T, Tsujino N, Hashimoto N, Matsui Y, Hori H, Yamamori H, Sugiyama N, Suwa T, Kishimoto T,  Hishimoto A, Usami M, Furihata R, Iwamoto K, Fujishiro H, Nakamura T, Mizuno K, Inagaki T, Katsumoto E,  Tomita H, Ohi K, Muraoka H, Atake K, Iida H, Nagasawa T, Fujita J, Yamamura S, Onitsuka T, Murata A,  Takayanagi Y, Noda H, Matsumura Y, Takezawa K, Iga J, Ichihashi K, Ogasawara K, Yamada H, Inada K, Hashimoto R Psychiatry Clin
Neurosci　73(10):
642-648, 2019
8 Genome-Wide Association Study Detected Novel Susceptibility Genes for Schizophrenia and Shared Trans-Populations/Diseases Genetic Effect Ikeda M, Takahashi A, Kamatani Y, Momozawa Y, Saito T, Kondo K, Shimasaki A, Kawase K, Sakusabe T, Iwayama Y, Toyota T, Wakuda T, Kikuchi M, Kanahara N, Yamamori H, Yasuda Y, Watanabe Y, Hoya S, Aleksic B, Kushima I, Arai H, Takaki M, Hattori K, Kunugi H, Okahisa Y, Ohnuma T, Ozaki N, Someya T, Hashimoto R, Yoshikawa T, Kubo M, Iwata N Schizophr Bull
45(4):824-834, 2019
9 Eye movement characteristics of schizophrenia and their association with cortical thickness. Morita K, Miura K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Azechi H, OkadaN, Koshiyama D, Shiino T, Fukunaga M, Watanabe Y, Ikeda M, Kasai K, Hashimoto R Psychiatry Clin
Neurosci 73(8):
508-509, 2019.8
10 Eye movement abnormalities and their association with cognitive impairments in schizophrenia. Morita K, Miura K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Azechi H, Okada N, Koshiyama D, Ikeda M, Kasai K, Hashimoto R Schizophrenia Research
209:255-262, 2019.7
11 A 1.5-Year Longitudinal Study of Social Activity in Patients With Schizophrenia. Ohi K, Sumiyoshi C, Fujino H, Yasuda Y, Yamamori H, Fujimoto M, Sumiyoshi T, Hashimoto R. Frontiers in psychiatry. 10 567-567. 2019.
2018 1 Comparative Analyses of Copy Number Variation in Autism Spectrum Disorder and Schizophrenia: Reveal Etiological Overlap and Biological Insights. Kushima I, (26名省略) Hashimoto R, (79名中28番目)（58名省略） Ozaki N,  Cell reports,
24(11):2838-2856,
2018
2 Role of subcortical structures on cognitive and social function in schizophrenia. Koshiyama D, Fukunaga M, Okada N, Yamashita F, Yamamori H, Yasuda Y, Fujimoto M, Ohi K, Fujino H, Watanabe Y, Kasai K, Hashimoto R.  Sci Rep, 8(1):1183,
2018
3 Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 controls via the ENIGMA consortium.  van Erp TGM, (8名中略）Hashimoto R,(179名中10番目）（168中略）Turner JA.  Biol Psychiatry,
84(9):644-654. 2018
4 Integrative analyses of de novo mutations provide deeper biological insights in autism spectrum disorder.  Takata A, Miyake N, Tsurusaki Y, Fukai R, Miyatake S, Koshimizu E, Kushima I, Okada T, Morikawa M, Uno Y, Ishizuka K, Nakamura K, Tsujii M, Yoshikawa T, Toyota T, Okamoto N, Hiraki Y, Hashimoto R, Yasuda Y, Saitoh S, Ohashi K, Sakai Y, Ohga S, Hara T, Kato M, Nakamura K, Ito A, Seiwa C, Shirahata E, Osaka H, Matsumoto A, Takeshita S, Tohyama J, Saikusa T, Matsuishi T, Nakamura T, Tsuboi T, Kato T, Suzuki T, Saitsu H, Nakashima M, Mizuguchi T, Tanaka F, Mori N, Ozaki N, Matsumoto N. Cell Rep, 16;22(3):
734-747, 2018
5 Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis.  Numata S, Umehara H, Ohmori T, Hashimoto R. Frontiers in
Pharmacology, section
Neuropharmacology.
9:1049, 2018
6 Analysis of the influence of microRNAs in Lithium Response in Bipolar Disorder. Frontiers in Psychiatry, section Behavioral and Psychiatric Genetics.  Reinbold C,（37名中略）Hashimoto R, (119名中39番目)（80名中略）Cichon S.  Frontiers in Psychiatry, section Behavioral and Psychiatric Genetics.
9:207, 2018
7 Semantic Memory Organization in Japanese Patients with Schizophrenia Examined with Category Fluency.  Sumiyoshi C, Fujino H, Sumiyoshi T, Yasuda Y, Yamamori H, Fujimoto M, Hashimoto R.  Frontiers in
Psychiatry, section
Psychopathology,
9:87, 2018
8 Plasma levels of soluble tumor necrosis factor receptor 2 (sTNFR2) are associated with hippocampal volume and cognitive performance in patients with schizophrenia.  Kudo N, Yamamori H, Ishima T, Nemoto K, Yasuda Y, Fujimoto M, Azechi H, Niitsu T, Numata S, Ikeda M, Iyo M, Ohmori T, Fukunaga M, Watanabe Y, Hashimoto K, Hashimoto R.  Int J
Neuropsychopharmacol
, 21(7):631-639, 2018
9 Genetic Overlap between General Cognitive Function and Schizophrenia: A Review of Cognitive GWASs. Ohi K, Sumiyoshi C, Fujino H, Yasuda Y, Yamamori H, Fujimoto M, Shiino T, Sumiyoshi T, Hashimoto R. Int. J. Mol.
Sci.(International
Journal of Molecular
Sciences,)
19, 3822, 2018
10 Longer telomeres in elderly schizophrenia are associated with long-term hospitalization in the Japanese population.  Zhang Y, Hishimoto A, Otsuka I, Watanabe Y, Numata S, Yamamori H, Boku S, Horai T, Someya T, Ohmori S, Hashimoto R, Sora I.  J Psychiatr Res,
103:161-166, 2018
11 Decreased serum pyridoxal levels in schizophrenia: meta-analysis and Mendelian randomization analysis.  Tomioka Y, Numata S, Kinoshita M, Umehara H, Watanabe S, Nakataki M, Iwayama Y, Toyota T, Ikeda M, Yamamori H, Shimodera S, Tajima A, Hashimoto R, Iwata N, Yoshikawa T, Ohmori T.   J Psychiatry Neurosci,
43(3):194-200, 2018
12 Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. International Consortium on Lithium Genetics (ConLi+Gen),(45名中略), Hashimoto R,  (113名中47番目) （65名中略）Baune BT. JAMA Psychiatry,
1;75(1):65-74, 2018
13 A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder.  Ikeda M, Takahashi A, Kamatani Y, Okahisa Y, Kunugi H, Mori N, Sasaki T, Ohmori T, Okamoto Y, Kawasaki H, Shimodera S, Kato T, Yoneda H, Yoshimura R, Iyo M, Matsuda K, Akiyama M, Ashikawa K, Kashiwase K, Tokunaga K, Kondo K, Saito T, Shimasaki A, Kawase K, Kitajima T, Matsuo K, Itokawa M, Someya T, Inada T, Hashimoto R, Inoue T, Akiyama K, Tanji H, Arai H, Kanba S, Ozaki N, Kusumi I, Yoshikawa T, Kubo M, Iwata N, COSMO team.  Mol Psychiatry,
23(3):639-647, 2018
14 Widespread white matter microstructural differences in schizophrenia across 4,322 individuals: results from the ENIGMA Schizophrenia DTI Working Group.  Kelly S,(46名中略),Hashimoto R,(158名中48番目）（109名中略） Donohoe G.  Mol Psychiatry,
23(5):1261-1269,
2018
15 Convergence of placenta biology and genetic risk for schizophrenia, Ursini G, Punzi G, Chen Q, Marenco S, Robinson J, Porcelli A, Hamilton E, Mitjans M, Maddalena G, Begemann M, Seidel J, Yamamori H, Jaffe A, Berman K, Egan M, Straub R, Colantuoni C, Blasi G, Hashimoto R, Rujescu D, Ehrenreich H, Bertolino A, Weinberger DR.   Nat Med,
24(6):792-801,
2018
16 Frequency of mental disorders among chronic pain patients with or without fibromyalgia in Japan.  Miki K, Nakae A, Shi K, Yasuda Y, Yamamori H, Fujimoto M, Ikeda M, Shibata M, Yukioka M, Hashimoto R.  Neuropsychopharmacology
 Reports, 38:167-174,
2018
17 Blood biomarkers for neuropsychiatric diseases.  Hashimoto R.  Psychiatry Clin Neurosci,
Editorial, 72:139, 2018
18 Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium.  Walton E, Hibar DP, van Erp TGM, Potkin SG, Roiz-Santianez R, Crespo-Facorro B, Suarez-Pinilla P, van Haren NEM, de Zwarte SMC, Kahn RS, Cahn W, Doan NT, Jorgensen KN, Gurholt TP, Agartz I, Andreassen OA, Westlye LT, Melle I, Berg AO, Morch-Johnsen L, Farden A, Flyckt L, Fatouros-Bergman H, Jonsson EG, Hashimoto R, (59名中26番目)Yamamori H, Fukunaga M, Jahanshad N, De Rossi P, Piras F, Banaj N, Spalletta G, Gur RE, Gur RC, Wolf DH, Satterthwaite TD, Beard LM, Sommer IE, Koops S, Gruber O, Richter A, Kramer B, Kelly S, Donohoe G, McDonald C, Cannon DM, Corvin A, Gill M, Di Giorgio A, Bertolino A, Lawrie S, Nickson T, Whalley HC, Neilson E, Calhoun VD, Thompson PM, Turner JA, Ehrlich S, Karolinska Schizophrenia Project consortium (KaSP). Psychol Med, 48(1):
82-94,2018.
19 Predicting work outcome in patients with schizophrenia: Influence of IQ decline.  Sumiyoshi C, Fujino H, Yamamori H, Kudo N, Azechi H, Fujimoto M, Yasuda Y, Ohi K, Sumiyoshi T, Hashimoto R. Schizophr Res,
201:172-179, 2018
20 Role of frontal white matter and corpus callosum on social function in schizophrenia.  Koshiyama D, Fukunaga M, Okada N, Morita K, Nemoto K, Yamashita F, Yamamori H, Yasuda Y, Fujimoto M, Kelly S, Jahanshad N, Kudo N, Azechi H, Watanabe Y, Donohoe G, Thompson PM, Kasai K, Hashimoto R.  Schizophr Res,
202:180-187, 2018
21 Abnormalities of eye movement are associated with work hours in schizophrenia.  Morita K, Miura K, Fujimoto M, Shishido E, Shiino T, Takahashi J, Yamamori H, Yasuda Y, Kudo N, Hirano Y, Koshiyama D, Okada N, Ikeda M, Onitsuka T, Ozaki N, Kasai K, Hashimoto R.  Schizophr Res,
202:420-422, 2018
22 Genome-wide Association Analysis of Eye Movement Dysfunction in Schizophrenia.  Kikuchi M, Miura K, Morita K, Yamamori H, Fujimoto M, Ikeda M, Yasuda Y, Nakaya A, Hashimoto R.  Sci Rep, 8(1):12347,
2018
23 Subcortical association with memory performance in schizophrenia: a structural magnetic resonance imaging study.  Koshiyama D, Fukunaga M, Okada N,Yamashita F, Yamamori H, Yasuda Y, Fujimoto M, Ohi K, Fujino H, Watanabe Y, Kasai K, Hashimoto R.  Transl Psychiatry.
8(1):20, 2018
2017 1 Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA-Schizophrenia consortium. Walton E, (24名中略）Hashimoto R (60名中25番目）（33名中略）Ehrlich S.  Acta Psychiatrica
Scandinavica,
135(5):439-447, 2017
2 Transethnic Replication Study to Assess the Association Between Clozapine-Induced Agranulocytosis/Granulocytopenia and Genes at 12p12.2 in a Japanese Population. Saito T, Ikeda M, Hashimoto R, Clozapine Pharmacogenomics Consortium of Japan (CPC-J), Iwata N. Biol Psychiatry, 82(1):
e9-e10, 2017
3 Microglia-derived neuregulin expression in psychiatric disorders. Ikawa D, Makinodan M, Iwata K, Ohgidani M, Kato T, Yamashita Y, Yamamuro K, Kimoto S, Toritsuka M, Yamauchi T, Fukami S, Yoshino H, Okumura K, Tanaka T, Wanaka A, Owada Y, Tsujii M, Sugiyama T, Tsuchiya K, Mori N, Hashimoto R, Matsuzaki H, Kanba S, Kishimoto T. Brain Behav Immun,
61:375-385, 2017
4 Human subcortical brain asymmetries in 15,847 people worldwide reveal effects of age and sex. Guadalupe T, (62名中略)　Hashimoto R,(160名中64番目)（95名中略）Francks C.  Brain Imaging and
Behaviour 11(5):
1497-1514, 2017
5 A Brief Assessment of Intelligence Decline in Schizophrenia as Represented by the Difference between Current and Premorbid IQ. Ohi K, Sumiyoshi C, Fujino H, Yasuda Y, Yamamori H, Fujimoto M, Sumiyoshi T, Hashimoto R. Frontiers in
Psyhiatry-Psyhopathology.
8:293, 2017
6 Effect of Clozapine on DNA Methylation in Peripheral Leukocytes from Patients with Treatment-Resistant Schizophrenia. Kinoshita M, Numata S, Tajima A, Yamamori H, Yasuda Y, Fujimoto M, Watanabe S, Umehara H, Shimodera S, Nakazawa T, Kikuchi M, Nakaya A, Hashimoto H, Imoto I, Hashimoto R, Ohmori T. Int J Mol Sci, 18(3):632,
2017
7 High-resolution copy number variation analysis of schizophrenia in Japan. Kushima I, Aleksic B, Nakatochi M, Shimamura T, Shiino T, Yoshimi A, Kimura H, Takasaki Y, Wang C, Xing J, Ishizuka K, Oya-Ito T, Nakamura Y, Arioka Y, Maeda T, Yamamoto M, Yoshida M, Noma H, Hamada S, Morikawa M, Uno Y, Okada T, Iidaka T, Iritani S, Yamamoto T, Miyashita M, Kobori A, Arai M, Itokawa M, Cheng MC, Chuang YA, Chen CH, Suzuki M, Takahashi T, Hashimoto R, Yamamori H, Yasuda Y, Watanabe Y, Nunokawa A, Someya T, Ikeda M, Toyota T, Yoshikawa T, Numata S, Ohmori T, Kunimoto S, Mori D, Iwata N, Ozaki N. Mol Psychiatry, 22(3):
430-440, 2017
8 Novel genetic loci associated with hippocampal volume. Hibar DP, (199名中略)　Hashimoto R,(332名中201番目)（130名中略）Ikram MA. Nat Commun, 18;8:13624,
2017
9 ENIGMA and the individual : Predicting factors that affect the brain in 35 countries worldwide. Thompson P, (29名中略）Hashimoto R, (71名中31番目）Wright M, Ye J, for the ENIGMA Consortium. NeuroImage, 145
(Pt B):389-408, 2017
10 The effect of duration of illness and antipsychotics on subcortical volumes in schizophrenia: Analysis of 778 subjects. Hashimoto N, Ito Y, Okada N, Yamamori H, Yasuda Y, Fujimoto M, Kudo N, Takemura A, Son S, Narita H, Yamamoto M, Tha KK, Katsuki A, Ohi K, Yamashita F, Koike S, Takahashi T, Nemoto K, Fukunaga M, Onitsuka T, Watanabe Y, Yamasue H, Suzuki M, Kasai K, Kusumi I, Hashimoto R, for COCORO. NeuroImage Clin,
17;563-569, 2017
11 High-speed and scalable whole-brain imaging in rodents and primates. Seiriki K, Kasai A, Hashimoto T, Schulze W, Niu M, Yamaguchi S, Nakazawa T, Inoue K, Uezono S, Takada M, Naka Y, Igarashi H, Tanuma M, Waschek JA, Ago Y, Tanaka KF, Hayata-Takano A, Nagayasu K, Shintani N, Hashimoto R, Kunii Y, Hino M, Matsumoto J, Yabe H, Nagai T, Fujita K, Matsuda T, Takuma K, Baba A, Hashimoto H. Neuron, 94:1085-1100,
2017
12 Altered sulcogyral patterns of orbitofrontal cortex in a large cohort of patients with schizophrenia. Isomura S, Hashimoto R, Nakamura M, Yamashita F, Jimbo S, Hirano Y, Yamamori H, Fujimoto M, Yasuda Y, Mears R, Onitsuka T. NPJ Schizophrenia,
3(1):3:1-4, 2017
13 Cardiogenic shock caused by left mid-ventricular obstruction in a patient with anorexia nervosa; A novel cardiac manifestation of refeeding syndrome. Sakamoto Y, Kioka H, Hashimoto R, Takeda S, Ohtani T, Yamaguchi O, Wasa M, Nakatani S, Sakata Y. Nutrition, 35:148-150,
2017
14 Eye movement as a biomarker of schizophrenia:Using an integrated eye movement score Morita K, Miura K, Fujimoto M, Yamamori H, Yasuda Y, Iwase M, Kasai K, Hashimoto R. Psychiatry Clin Neurosci,
71(2):104-114, 2017
15 Optimizing Outcomes in Clozapine Rechallenge Following Neutropenia Using Human Leukocyte Antigen Typing: A Case Report. Yamaki N, Hishimoto A, Otsuka I, Sasada T, Boku S, Saito T, Yasuda Y, Yamamori H, Ikeda M, Ikeda M, Sora I, Iwata N, Hashimoto R. Psychiatry Clin Neurosci,
71(4):289-290, 2017
16 Estimated cognitive decline in patients with schizophrenia: A multi-center study. Fujino H, Sumiyoshi C, Yasuda Y, Yamamori H, Fujimoto M, Fukunaga M, Miura K, Takebayashi Y, Okada N, Isomura S, Kawano N, Toyomaki A, Kuga H, Isobe M, Oya K, Okahisa Y, Takaki M, Hashimoto N, Kato M, Onitsuka T, Ueno T, Ohnuma T, Kasai K, Ozaki N, Sumiyoshi T, Imura O, Hashimoto R. Psychiatry Clin Neurosci,
71(5):294-300, 2017
17 Differential gene expression profiles in neurons generated from lymphoblastoid B-cell line-derived iPS cells from monozygotic twin cases with treatment-resistant schizophrenia and discordant responses to clozapine. Nakazawa T, Kikuchi M, Ishikawa M, Yamamori H, Nagayasu K, Matsumoto T, Fujimoto M, Yasuda Y, Fujiwara M, Okada S, Matsumura K, Kasai A, Hayata-Takano A, Shintani N, Numata S, Takuma K, Akamatsu W, Okano H, Nakaya A, Hashimoto H, Hashimoto R. Schizophr Res, 181:75-82,
2017
18 IMPACT OF INTELLIGENCE DECLINE ON WORK OUTCOME IN PATIENTS WITH SCHIZOPHRENIA . Sumiyoshi C, Sumiyoshi T, Fujino H, Yamamori H, Yasuda Y, Kudo N, Fujimoto M, Ikeda M, Hashimoto R. SCHIZOPHRENIA BULLETIN,43:S128-S128
19  [Merits and Demerits of High-dose Psychotropic Polypharmacy in Schizophrenia from Guidelines]. Hashimoto R, Yasuda Y, Fujimoto M, Yamamori H. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. 119(3) 185-191
2016 1  Association of copy number polymorphisms at the promoter and translated region of COMT with Japanese patients with schizophrenia. Higashiyama R, Ohnuma T, Takebayashi Y, Hanzawa R, Shibata N, Yamamori H, Yasuda Y, Kushima I, Aleksic B, Kondo K, Ikeda M, Hashimoto R, Iwata N, Ozaki N, Arai H Am J Med Genet B
Neuropsychiatr Genet
171(3):447-457, 2016
2 Sensory cognitive abnormalities of pain in autism spectrum disorder: a case control study Yasuda Y, Hashimoto R, Nakae A, Kang H, Ohi K, Yamamori H, Fujimoto M, Hagihira S, Takeda M Ann Gen Psychiatry 15:8,
2016
3 Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects. Kamada Y, Hashimoto R, Yamamori H, Yasuda Y, Takehara T, Fujita Y, Hashimoto K, Miyoshi E BBA Clin 5:101-107,
2016
4 Prostaglandin D2 signaling mediated by the CRTH2 receptor is involved in MK-801-induced cognitive dysfunction Onaka Y, Shintani N, Nakazawa T, Knoh T, Ago Y, Matsuda T, Hashimoto R, Ohi K, Hirai H, Nagata KY, Nakamura M, Hayata-Takano A, Nagayasu K, Takuma K, Ogawa A, Baba A, Hashimoto H  Behav Brain Res 314:
77-86, 2016
5 The regulation of soluble receptor for AGEs contributes to carbonyl stress in schizophrenia Miyashita M, Watanabe T, Ichikawa T, Toriumi K, Horiuchi Y, Kobori A, Kushima I, Hashimoto R, Fukumoto M, Koike S, Ujike H, Arinami T, Tatebayashi Y, Kasai K, Takeda M, Ozaki N, Okazaki Y, Yoshikawa T, Amano N, Washizuka S, Yamamoto H, Miyata T, Itokawa M, Yamamoto Y, Arai M Biochem Biophys Res
Commun 479(3):447-452,
2016
6 Pharmacogenomic study of clozapine-induced agranulocytosis/granulocytopenia in a Japanese population Saito T, Ikeda M, Mushiroda T, Ozeki T, Kondo K, Shimasaki A, Kawase K, Hashimoto S, Yamamori H, Yasuda Y, Fujimoto M, Ohi K, Takeda M, Kamatani Y, Numata S, Ohmori T, Ueno S, Makinodan M, Nishihata Y, Kubota M, Kimura T, Kanahara N, Hashimoto N, Fujita K, Nemoto K, Fukao T, Suwa T, Noda T, Yada Y, Takaki M, Kida N, Otsuru T, Nurakami M, Takahashi A, Kubo M, Hashimoto R, Iwata N Biol Psychiatry 80:
636-642,2016
7 Cognitive enophenotypes of modern and extinct hominins associated with NTNG gene paralogs Prosselkov P, Hashimoto R, Polygalov D, Ohi K, Zhang Qi, McHugh T, Takeda M, Itohara S Biomedical Genetics
and Genomics 1(1): 5-13,
2016
8 Whole-exome sequencing and neurite outgrowth analysis in autism spectrum disorder Hashimoto R, Nakazawa T, Tsurusaki Y, Yasuda Y, Nagayasu K, Matsumura K, Kawashima H, Yamamori H, Fujimoto M, Ohi K, Umeda-Yano S, Fukunaga M, Fujino H, Kasai A, Hayata-Takano A, Shintani N, Takeda M, Matsumoto N, Hashimoto H J Hum Genet 61(3):
199-206, 2016
9 De novo POGZ mutations in sporadic autism disrupt the DNA-binding activity of POGZ Matsumura K, Nakazawa T, Nagayasu K, Gotoda-Nishimura N, Kasai A, Hayata-Takano A, Shintani N, Yamamori H, Yasuda Y, Hashimoto R, Hashimoto H J Mol Psychiatry 4:1,
2016
10 Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study Hou L, (38名中略）Hashimoto R, (124名中40番目）（83名中略）Schulze T.G. Lancet
12;387(10023):1085-93,
2016
11 Modeling neurological diseases with induced pluripotent cells reprogrammed from immortalized lymphoblastoid cell lines Fujimori K, Tezuka T, Ishiura H, Mitsui J, Doi K, Yoshimura J, Tada H, Matsumoto T, Isoda M, Hashimoto R, Nattori N, Takahashi T, Morishita S, Tsuji S, Akamatsu W, Okano H Mol Brain 9(1):88, 2016
12 Subcortical Brain Volume Abnormalities in 2,028 Individuals with Schizophrenia and 2,540 Healthy Controls via the ENIGMA Consortium van Erp T, （54名中略)Hashimoto R,（58名中56番目）Thompson P, Turner J, for the ENIGMA Schizophrenia Working Group Mol Psychiatry 21(4):
547-553, 2016
13 Abnormal asymmetries in subcortical brain volume in schizophrenia Okada N, Fukunaga M, Yamashita F, Koshiyama D, Yamamori H, Ohi K, Yasuda Y, Fujimoto M, Watanabe Y, Yahata N, Nemoto K, Hibar D, van Erp T, Fujino H, Isobe M, Isomura S, Natsubori T, Narita H, Hashimoto N, Miyata J, Koike S, Takahashi T, Yamasue H, Matsuo K, Onitsuka T, Iidaka T, Kawasaki Y, Yoshimura R, Watanabe Y, Suzuki M, Turner J, Takeda M, Thompson P, Ozaki N, Kasai K, Hashimoto R, COCORO Mol Psychiatry 21:
1460-1466, 2016
14 Emerging Roles of ARHGAP33 in Intracellular Trafficking of TrkB and Pathophysiology of Neuropsychiatric Disorders Nakazawa T, Hashimoto R, Sakoori K, Sugaya Y, Tanimura A, Hashimotodani Y, Ohi K, Yamamori H, Yasuda Y, Umeda-Yano S, Kiyama Y, Konno K, Inoue T, Yokoyama K, Inoue T, Numata S, Ohnuma T, Iwata N, Ozaki N, Hashimoto H, Watanabe M, Manabe T, Yamamoto T, Takeda M, Kano M Nat Commun  7:
10594, 2016
15 Novel genetic loci underlying human intracranial volume identified through genome-wide association Adams H, (203名中略)　Hashimoto R,(341名中205番目)（134名中略）Thompson P Nat Neurosci 19(12):
1569-1582, 2016
16 Going longitudinal in biological psychiatric research: all things considered Gould T.D., Hashimoto R, Schulze T.G.  Neurosci Res 102(2016):
1-3, 2016
17 Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-A multicenter pilot analysis Setoyama D, Kato T, Hashimoto R, Kunugi H, Hattori K, Hayakawa K, Sato-Kasai M, Shimokawa N, Kaneko S, Yoshida S, Goto Y, Yasuda Y, Yamamori H, Ohgidani M, Sagata N, Miura D, Kang D, Kanba S PLoS One
11(12):e0165267, 2016
18 The multidimensional anatomy of "modern type depression" in Japan: A proposal for a different diagnostic approach to depression beyond the DSM-5 Kato T, Hashimoto R, Hayakawa K, Kudo H, Watabe M, Teo A.R., Kanba S Psychiatry Clin Neurosci
Frontier Review 70(1):
7-23, 2016
19 Clozapine improved the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in a patient with treatment-resistant schizophrenia Fujimoto M, Hashimoto R, Yamamori H, Yasuda Y, Ohi K, Iwatani H, Isaka Y, Takeda M Psychiatry Clin Neurosci
70:469, 2016
20 Usefulness of the Wechsler Intelligence Scale short form for assessing functional outcomes in patients with schizophrenia Sumiyoshi C, Fujino H, Sumiyoshi T, Yasuda Y, Yamamori H, Ohi K, Fujimoto M, Takeda M, Hashimoto R Psychiatry Res 245:
371-378, 2016
21 Polygenetic Components for Schizophrenia, Bipolar Disorder and Rheumatoid Arthritis Predict Risk of Schizophrenia Ohi K, Kikuchi M, Ikeda M, Yamamori H, Yasuda Y, Fujimoto M, Fujino H, Miura K, Fukunaga M, Nakaya A, Iwata N, Hashimoto R Schizophr Res  175:
226-229, 2016
22 Predicting employment status and subjective quality of life in patients with schizophrenia Fujino H, Sumiyoshi C, Sumiyoshi T, Ysuda Y, Yamamori H, Ohi K, Fujimoto M, *Hashimoto R, Takeda M, Imura O Schizophrenia Research:
Cognition 3:20-25, 2016
23 A significant causal association between C-reactive protein levels and schizophrenia Inoshita M, Numata S, Tajima A, Kinoshita M, Umehara H, Nakataki M, Ikeda M, Maruyama M, Yamamori H, Kanazawa T, Shimodera S, Hashimoto R, Imoto I, Yoneda H, Iwata N, Ohmori T Sci Rep  6:26105, 2016
24 Semantic memory organization in Japanese patients with schizophrenia examined with category fluency. Sumiyoshi C, Fujino H, Sumiyoshi T, Yasuda Y, Yamamori H, Ohi K, Fujimoto M, Hashimoto R. INTERNATIONAL JOURNAL OF PSYCHOLOGY. 51 150-150.
25 Studies on the molecular mechanism of clozapine action with iPSC technology. Fujiwara M, Kikuchi M, Nagayasu K, Nakazawa T, Yamamori H, Kasai A, Hayata-Takano A, Shintani N, Fujimoto M, Yasuda Y, Ishikawa M, Akamatsu W, Okano H, Nakaya A, Hashimoto H, Hashimoto R. JOURNAL OF PHARMACOLOGICAL SCIENCES. 130(3) S254
26 Assessment of a multi-assay biological diagnostic test for mood disorders in a Japanese population. Yamamori H, Ishima T, Yasuda Y, Fujimoto M, Kudo N, Ohi K, Hashimoto K, Takeda M, Hashimoto R. Neuroscience letters. 612 167-171.
2015 1 Saliency-guided eye movement during free-viewing in schizophrenic patients. Yoshida M, Miura K, Hashimoto R, Fujimoto M, Yamamori H, Yasuda Y, Ohi K, Fukunaga M, Takeda M, Isa T Journal of vision 15(12) 61-61 2015.09.01
2 Glutamate Networks Implicate Cognitive Impairments in Schizophrenia: Genome-Wide Association Studies of 52 Cognitive Phenotypes. Ohi K, Hashimoto R, Ikeda M, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S, Fukunaga M, Fujino H, Watanabe Y, Iwase M, Kazui H, Iwata N, Weinberger D, Takeda M. Schizophrenia bulletin. 41(4) 909-18.2015.07
3 Imaging Genetics and Psychiatric Disorders CURRENT MOLECULAR MEDICINE. Hashimoto R, Ohi K, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S, Watanabe Y, Fukunaga M, Takeda M. Imaging Genetics and Psychiatric Disorders CURRENT MOLECULAR MEDICINE. 15(2) 168-175.2015
2014 1 Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats  Nakai K, Nakae A, Hashimoto R, Mashimo T, Hosokawa K J Oral Facial Pain
Headache. 2014
Winter;28(1):61-7.2014.1
2 Differential Effects of Common Variants in SCN2A on General Cognitive Ability, Brain Physiology, and messenger RNA Expression in Schizophrenia Cases and Control Individuals Dickinson D, Straub RE, Trampush JW, Gao Y, Feng N, Xie B, Shin JH, Lim HK, Ursini G, Bigos KL, Kolachana B, Hashimoto R, Takeda M, Baum GL, Rujescu D, Callicott JH, Hyde TM, Berman KF, Kleinman JE, Weinberger DR   JAMA Psychiatry 1;
71(6):647-56, 2014
3 Association between genetic polymorphism rs2952768, close to the METTL21A and CREB1 genes, and intellectual ability in healthy subjects Nishizawa D, Ohi K, Hashimoto R, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S, Takeda M, Ikeda K  Journal of Addiction
Research & Therapy5(2):
1000178, 2014
4 Behavioral characterization of mice overexpressing human dysbindin-1  Shintani N, Onaka Y, Hashimoto R, Takamura H, Nagata T, Umeda-Yano S, Mouri A, Mamiya T, Haba R, Matsuzaki S, Katayama T, Yamamori H, Nakazawa T, Nagayasu K, Ago Y, Yagasaki Y, Nabeshima T, Takeda M, Hashimoto H Molecular Brain 9;7(1):
74, 2014
5 Failure of Failure of replicating the association between hippocampal volume and 3 single-nucleotide polymorphisms identified from theEuropean genome-wide association study in Asian populations  Li M, Ohi K, Chen C, He Q, Lu JW, Chen C. Luo XJ, Dong Q, Hashimoto R, Su B Neurobiology of Aging
35(12):2883e.1-2, 2014
6 Aberrant DNA methylation of blood in schizophrenia by adjusting for estimated cellular proportions Kinoshita M, Numata S, Tajima A, Ohi K, Hashimoto R, Shimodera S, Imoto I, Takeda M, Ohmori T NeuroMolecular Medicine
16:697-703, 2014
7 A functional polymorphism of the GTP cyclohydrolase I gene predicts attention performance Yasuda Y, Hashimoto R, Ohi K, Yamamori H, Fujimoto M, Umeda-Yano S, Fujino H, Horiguchi M, Takeda M, Ichinose H   Neurosci Lett 566(2014):
46-49, 2014
8 Expression analysis of the genes identified in GWAS of the postmortem brain tissues from patients with schizophrenia Umeda-Yano S, Hashimoto R, Yamamori H, Wickertd CS, Yasuda Y, Ohi K, Fujimoto M, Ito A, Takeda M  Neurosci Lett 568(2014):
12-16, 2014
9 Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, Ohi K, Umeda-Yano S, Ito A, Ohmori T, Hashimoto K, Takeda M Neurosci Lett 582:93-8,
2014
10 Neuromelanin magnetic resonance imaging reveals increased dopaminergic neuron activity in the substantia nigra of patients with schizophrenia Watanabe Y, Tanaka H, Tsukabe A, Kunitomi Y, Nishizawa M, Hashimoto R, Yamamori H, Fujimoto M, Fukunaga M, Tomiyama N PLos One 11:9(8):
e104619, 2014
11 Increased behavioral and neuronal responses to a hallucinogenic drug in PACAP heterozygous mutant mice Hazama K, Hayata-Takano A, Uetsuki K, Kasai A, Encho N, Shintani N, Nagayasu K, Hashimoto R, Reglodi D, Miyakawa T, Nakazawa T, Baba A, Hashimoto H   PLoS One 20;9(2):
e89153, 2014
12 Replication of enhanced carbonyl stress in a subpopulation of schizophrenia Miyashita M, Arai M, Yuzawa H, Ichikawa T, Nohara I, Arai M, Obata N, Toriumi K, Kobori A, Niizato K, Ooshima K, Kushima I, Hashimoto R, Fukumoto M, Koike S, Toyota T, Ujike H, Arinami T, Kasai K, Takeda M, Ozaki N, Okazaki Y, Yoshikawa T, Amano N, Miyata T, Itokawa M Psychiatry and Clinical
Neurosciences  68(1):
83-4, 2014
13 A functional polymorphism (C-824T) of the tyrosine hydroxylase gene affects intelligence quotient in schizophrenia Horiguchi M, Ohi K, Hashimoto R, Hao Q, Yasuda Y, Yamamori H, Fujimoto M, Umeda-Yano S, Takeda M, Ichinose H  Psychiatry and Clinical
Neurosciences 68(6):
456-62,  2014
14 Performance on the Wechsler Adult Intelligence Scale-III in Japanese patients with schizophrenia Fujino H, Sumiyoshi C, Sumiyoshi T, Yasuda Y, Yamamori H, Ohi K, Fujimoto M, Umeda-Yano S, Higuchi A, Hibi Y, Matsuura Y, Hashimoto R, Takeda M, Imura O Psychiatry and Clinical
Neurosciences　68(7):
534-541, 2014
15 Relation between remission status and attention in patients withn schizophrenia Fukumoto M, Hashimoto R, Ohi K, Yasuda Y, Yamamori H, Umeda-Yano S, Iwase M, Kazui H, Takeda M   Psychiatry and Clinical
Neurosciences,
68(3):234-41, 2014
16 Opioid therapy for knee osteoarthritis and postoperative persistent pain after knee arthroplasty Miki K, Hashimoto R, Shi K, Yukioka M Rheumatology 53(10):
1723-4. 2014
17 Meta-analyses of bloo homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia Nishi A, Numata S, Tajima A, Kinoshita M, Kikuchi K, Shimodera S, Tomotake M, Ohi K, Hashimoto R, Imoto I, Takeda M, Ohmori T Schizophrenia Bulletin
40(5):1154-63, 2014
18 An integrated eye movement score as a neurophysiological marker of schizophrenia Miura K, Hashimoto R, Fujimoto M, Yamamori H, Yasuda Y, Ohi K, Umeda-Yano S, Fukunaga M, Iwase M, Takeda M Schizophrenia Research
160(1-3):228-9, 2014
19 Direct induction of ramified microglia-like cells from human monocytes: Dynamic microglial dysfunction in Nasu-Hakola disease Ohgidani M, Kato T.A., Setoyama D, Sagata N, Hashimoto R, Shigenobu K, Yoshida T, Hayakawa K, Shimokawa N, Miura D, Utsumi H, Kanba S Scientific Reports
14;4:4957, 2014 
20 Central CRTH2, a second prostaglandin D2 receptor, mediates emotional impairment in the lipopolysaccharide and tumor-induced sickness behavior model Haba R, Shintani N, Onaka Y, Kanoh T, Wang H, Takenaga R, Hayata A, Hirai H, Nagata K, Nakamura M, Kasai A, Hashimoto R, Nagayasu K, Nakazawa T, Hashimoto H, Baba A The Journal of
Neuroscience 12;34(7):
2514-23, 2014
21 Common variants at 1q36 are associated with superior frontal gyrus volume Hashimoto R, Ikeda M, Yamashita F, Ohi K, Yamamori H, Yasuda Y, Fujimoto M, Fukunaga M, Nemoto K, Takahashi T, Ochigi M, Onitsuka T, Yamasue H, Matsuo K, Iidaka T, Iwata N, Suzuki M, Takeda M, Kasai K, Ozaki N Translational Psychiatry
4:e472, 2014
22 Cognitive inflexibility in Japanese adolescents and adults with autism spectrum disorders Yasuda Y, Hashimoto R, Ohi K, Yamamori H, Fujimoto M, Umeda-Yano S, Fujino H, Takeda M Workd J Psychiatr
22;4(2):42-48, 2014
23 Transcriptome analysis of distinct mouse strains reveals kinesin light chain-1 splicing as an amyloid-β accumulation modifier. Morihara T, Hayashi N, Yokokoji M, Akatsu H, Silverman MA, Kimura N, Sato M, Saito Y, Suzuki T, Yanagida K, Kodama TS,Tanaka T, Okochi M, Tagami S, Kazui H, Kudo T, Hashimoto R, Itoh N, Nishitomi K, Yamaguchi-Kabata Y, Tsunoda T,Takamura H, Katayama T, Kimura R, Kamino K, Hashizume Y, Takeda M. Proc Natl Acad
Sci U S A. 111(7):
2638-43, 2014
24 Studies on the molecular mechanism of clozapine action with iPSC technology Fujiwara M, Kikuchi M, Nagayasu K, Nakazawa T, Yamamori H, Kasai A, Hayata-Takano A, Shintani N, Fujimoto M, Yasuda Y, Ishikawa M, Akamatsu W, Okano H, Nakaya A, Hashimoto H, Hashimoto R. JOURNAL OF PHARMACOLOGICAL SCIENCES, 130(3) S254
25 Glutamate Networks Implicate Cognitive Impairments in Schizophrenia; Genome-wide Association Studies of 52 Cognitive Phenotypes Hashimoto R, Ohi K, Ikeda M, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S, Fukunaga M, Fujino H, Watanabe Y, Iwase M, Kazui H, Iwata N, Weinberger D, Takeda M. NEUROPSYCHOPHARMACOLOGY, 39 S406-S407, 2014.12
26 Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neuroscience letters. Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, Ohi K, Umeda-Yano S, Ito A, Ohmori T, Hashimoto K, Takeda M. Changes in plasma D-serine, Neuroscience letters. 582 93-8, 2024.10.17
27 Common variants at 1p36 are associated with superior frontal gyrus volume Hashimoto R, Ikeda M, Yamashita F, Ohi K, Yamamori H, Yasuda Y, Fujimoto M, Fukunaga M, Nemoto K, Takahashi T, Tochigi M, Onitsuka T, Yamasue H, Matsuo K, Iidaka T, Iwata N, Suzuki M, Takeda M, Kasai K, Ozaki N. TRANSLATIONAL PSYCHIATRY, 4 e472, 2024.10
28 Genetic risk variants of schizophrenia associated with left superior temporal gyrus volume. Ohi K, Hashimoto R, Ikeda M, Yamashita F, Fukunaga M, Nemoto K, Ohnishi T, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S, Watanabe Y, Iwata N, Weinberger D, Takeda M. Cortex; a journal devoted to the study of the nervous system and behavior 58 23-6, 2014.09
29 Performance on the Wechsler Adult Intelligence Scale-III in Japanese patients with schizophrenia. Fujino H, Sumiyoshi C, Sumiyoshi T, Yasuda Y, Yamamori H, Ohi K, Fujimoto M, Umeda-Yano S, Higuchi A, Hibi Y, Matsuura Y, Hashimoto R, Takeda M, Imura O. Psychiatry and clinical neurosciences, 68(7) 534-41, 2014.07
30 Cognitive inflexibility in Japanese adolescents and adults with autism spectrum disorders. Yasuda Y, Hashimoto R, Ohi K, Yamamori H, Fujimoto M, Umeda-Yano S, Fujino H, Takeda M. World journal of psychiatry, 4(2) 42-8, 2014.06.22
31 Functional polymorphism (C-824T) of the tyrosine hydroxylase gene affects IQ in schizophrenia. Horiguchi M, Ohi K, Hashimoto R, Hao Q, Yasuda Y, Yamamori H, Fujimoto M, Umeda-Yano S, Takeda M, Ichinose H. sychiatry and clinical neurosciences, 68(6) 456-62, 2014.06
32 Intermediate phenotype studies in schizophrenia Hashimoto R, Ohi K, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S, Takeda M. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 17 13-13, 2014.06
33 Association between genetic polymorphism rs2952768, close to the METTL21A and CREB1 genes, and intellectual ability in healthy subjects. Nishizawa D, Ohi K, Hashimoto R, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S, Takeda M, Ikeda K. J Addict Res Ther, 5(2) 1000178, 2014.06
34 Expression analysis of the genes identified in GWAS of the postmortem brain tissues from patients with schizophrenia. Umeda-Yano S, Hashimoto R, Yamamori H, Weickert C, Yasuda Y, Ohi K, Fujimoto M, Ito A, Takeda M. Neuroscience letters, 568 12-6, 2015.05.07
35 Neuromelanin magnetic resonance imaging reveals increased dopaminergic neuron activity in the substantia nigra of patients with schizophrenia. Watanabe Y, Tanaka H, Tsukabe A, Kunitomi Y, Nishizawa M, Hashimoto R, Yamamori H, Fujimoto M, Fukunaga M, Tomiyama N. PloS one, 9(8) e104619, 2014
36 Duplication of the NPHP1 gene in patients with autism spectrum disorder and normal intellectual ability: a case series. Yasuda Y, Hashimoto R, Fukai R, Okamoto N, Hiraki Y, Yamamori H, Fujimoto M, Ohi K, Taniike M, Mohri I, Nakashima M, Tsurusaki Y, Saitsu H, Matsumoto N, Miyake N, Takeda M. Annals of general psychiatry, 13 22-22, 2014
37 An integrated eye movement score as a neurophysiological marker of schizophrenia. Miura K, Hashimoto R, Fujimoto M, Yamamori H, Yasuda Y, Ohi K, Umeda-Yano S, Fukunaga M, Iwase M. Schizophrenia research, 160(1-3) 228-9.
2013 1 Genome-wide association study of atypical psychosis Kanazawa T, Ikeda M, Glatt S.J, Tsutsumi A, Kikuyama H, Kawamura Y, Nishida N, Miyagawa T, Hashimoto R, Takeda M, Sasaki T, Tokunaga K, Koh J, Iwata N, Yoneda H Am J Med Genet B
Neuropsychiatry Genet
162(7):679-86, 2013
2 Genome-wide association study of cognitive decline in schizophrenia Hashimoto R, Ikeda M, Ohi K, Yasuda Y, Yamamori H, Fukumoto M, Umeda-Yano S, Dickinson D, Aleksic B, Iwase M, Kazui H, Ozaki N, Weinberger DR, Iwata N, Takeda M Am J Psychiatry
170(6):683-684, 2013
3 How to diagnose the 22q11.2 deletion syndrome in patients with schizophrenia: a case report Ohi K, Hashimoto R, Yamamori H, Yasuda Y, Fujimoto M, Nakatani N, Kamino K, Takeda M Annals of General
Psychiatry 12(1):29,
2013
4 The impact of the genome-wide supported variant in the cyclin M2 gene on gray matter morphology in schizophrenia Ohi K, Hashimoto R, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S, Fukunaga M, Watanabe Y, Iwase M, Kazui H, Takeda M Behav Brain Funct 9(1):
40, 2013
5 Responsiveness of jaw motor activation to arousals during sleep in patients with obstructive sleep apnea syndrome Kato T, Katase T, Yamashita S, Sugita H, Muraki H, Mikami A, Okura M, Ohi M, Masuda Y, Taniguchi M J Clin Sleep Med 9 (8) ：
759-765, 2013
6 Influence of the NRGN gene on intellectual ability in schizophrenia Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Yamamori H, Umeda-Yano S, Fujimoto M, Iwase M, Kazui H, Takeda M J Hum Genet 58(10):
700-5, 2013
7  Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia Ikeda M, Okahisa Y, Aleksic B, Won M, Kondo N, Naruse N, Aoyama-Uehara K, Sora I, Iyo M, Hashimoto R, Kawamura Y, Ninishida N, Miiyagawa T, Takeda M, Sasaki T, Tokunaga K, Ozaki N, Ujike H, Iwata N Neuropsychopharmacology
38(10):1864-70, 2013
8 Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine Yamamori H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, Fujimoto M, Umeda-Yano S, Ito A, Hashimoto K, Takeda M Neurosci Lett
556(2013):37-41, 2013
9 Assessment of response to Lithium maintenance treatment in bipolar disorder: A consortium on Lithium genetics (ConLiGen) report Manchia M, Adli M, Akula N, Ardau R, Aubry J.M, Backlund L, Banzato C, Baune B, Bellivier F, Bengeser S, Biernacka J, Brichant-Petitjean C, Bui E, Calkin C, Cheng A, Chillotti C, Cichon S, Clark S, Czerski P, Dantas C, Zompo M, DePaulo J, Detera-Wadleigh S, Etain B, Falkai P, Frisen L, Frye M, Fullerton J, Gard S, Garnham J, Goes F, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Hobann R, Hou L, Jamain S, Kahn J, Kassem L, Kato T, Kelsoe J, Kittel-Schneider S, Kliwicki S, Kuo P, Kusumi I, Laje G, Lavebratt C, Leboyer M, Leckband S, Jaaramillo C, Maj M, Malafosse A, Martinsson L, Masui T, Mitchell P, Mondimore F, Monteleone P, Nallet A, Neuner M, Novak T, O'Donovan C, Osby U, Ozaki N, Perlis R, Pfennig A, Potash J, Reich-Erkelenz D, Reif A, Reininghaus E, Richardson S, Rouleau G, Rybakowski J, Schalling M, Schofield P, Schubert O, Schweizer B, Seemuller F, Grigoroiu-Serbanescu M, Severino G, Seymour L, Slaney C, Smoller J, Squassina A, Stamm T, Steele J, Stopkova P, Tighe S, Tortorella A, Turecki G, Wray N, Wright A, Zandi P, Zilles D, Bauer M, Rietschel M, McMahon F, Schulze T, Alda M PLoS One 8(6): e65636,
2013
10 Functional analysis of deep intronic SNP rs13438494 in intron 24 of PCLO gene Seo S, Takayama K, Uno K, Ohi K, Hashimoto R, Nishizawa D, Ikeda K, Miyamoto y, Ozaki N, Nabeshima T, Nitta A PLoS One 8(10): e76960,
2013
11 An association analysis of the cardiomyopathy-associated 5(CMYA5) gene with schizophrenia in a Japanese population Furukawa M, Tochigi M, Otowa T, Arinami T, Inada T, Ujike H, Watanabe Y, Iwata N , Itokawa M, Kunugi H, Hashimoto R, Ozaki N, Kakiuchi C, Kasai K, Sasaki T Psychiatr Genet 23(4):
179-180, 2013
12 Analysis of the VAV3 as candidate gene for schizophrenia: evidences from voxel based morphometry and mutation screening Aleksic B., Kushima I, Hashimoto R, Ohi K, Ikeda M, Yoshimi A, Nakamura Y, Ito Y, Okochi T, Fukuo Y, Yasuda Y, Fukumoto M, Yamamori H, Ujike H, Suzuki M, Inada T, Takeda M, Kaibuchi K, Iwata N, Ozaki N Schizophrenia Bulletin
39(3):720-8, 2013
13 The regulation of gene expression involved in TGF-β signaling by ZNF804A, a risk gene for schizophrenia Umeda-Yano S, Hashimoto R, Yamamori H, Okada T, Yasuda Y, Ohi K, Fukumoto M, Ito A, Takeda M Schizophr Res 146(1-3):
273-8, 2013
14 Replication in a Japanese population that a MIR30E gene variation is associated with schizophrenia Watanabe Y, Iijima Y, Egawa J, Nunokawa A, Kaneko N, Arinami T, Ujike H, Inada T, Iwata N, Kunugi H, Itokawa M, Sasaki T, Ozaki N, Hashimoto R, Shibuya M, Igeta H, Someya T Schizophr Res 150(2-3):
596-7, 2013
15 The AKT1 gene is associated with attention and brain morphology in schizophrenia Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Nemoto K, Ohnishi T, Yamamori H, Takahashi H, Iike N, Kamino K, Yoshida T, Azechi M, Ikezawa K, Tanimukai H, Tagami S, Morihara T, Okochi M, Tanaka T, Kudo T, Iwase M, Kazui H, Takeda M World J Biol Psychiatry
14(2):100-13, 2013
16 The KCNH2 gene is associated with neurocognition and the risk of schizophrenia Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Yamamori H, Kamino K, Morihara T, Iwase M, Kazui H, Takeda M World J Biol Psychiatry
14(2):114-20, 2013
17 [How far have biomarkers in psychiatry advanced?] Hashimoto R, Yasuda Y, Yamamori H, Fujimoto M, Ohi K, Fukumoto M, Umeda-Yano S, Takeda M. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. 115(12) 1203-10, 2013
2012 1 Functional genetic variation at the NRGN gene and schizophrenia: evidence from a gene-based case-control study and gene expression analysis Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Yamamori H, Umeda-Yano S, Okada T, Kamino K, Morihara T, Iwase M, Kazui H, Numata S, Ikeda M, Ohmura T, Iwata N, Ueno S, Ozaki N, Ohmori T, Arai H, Takeda M American Journal of
Medical Genetics Part B:
Neuropsychiatric
Genetics,159B(4):405-13,
2012
2 No Associations Found between the Genes Situated at 6p22.1, HIST1H2BJ, PRSS16 and PGBD1 in Japanese Patients Diagnosed With Schizophrenia Kitazawa M, Ohnuma T, Takebayashi Y, Shibata N, Baba H, Ohi K, Yasuda Y, Nakamura Y, Aleksic B, Yoshimi A, Okochi T, Ikeda M, Naitoh H, Hashimoto R, Iwata N, Ozaki N, Takeda M American Journal of
Medical Genetics Part B:
Neuropsychiatric Genetics,
 159B(4): 456-64, 2012
3 The role of cholesterol in the association of endoplasmic reticulum membranes with mitochondria Fujimoto M, Hayashi T, Su TP Biochemical and
Biophysical Research
Communications
417:635-639, 2012
4 The value of cerebrospinal fluid tap test for predicting shunt effectiveness in idiopathic normal pressure hydrocephalus Ishikawa M, Hashimoto M, Mori E, Kuwana N, Kazui H Fluids Barriers CNS 9(1):
1, 2012
5 The lifetime of UDP-galactose:ceramide galactosyltransferase is controlled by a distinct endoplasmic reticulum-associated degradation (ERAD) regulated by sigma-1 receptor chaperones Hayashi T, Hayashi E, Fujimoto M, Sprong H, Su TP J Biol Chem 287(51):
43156-69, 2012
6 Personality traits and schizophrenia: evidence from a case-control study and meta-analysis Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Yamamori H, Iwase M, Kazui H, Takeda M Neurosci Lett 513(3):
204-208, 2012
7 A promoter variant in the chitinase 3-like 1 gene is associated with serum YKL-40 level and personality trait Yamamori H, Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Kasahara E, Sekiyama A, Umeda-Yano S, Okada T, Iwase M, Kazui H, Ito A, Takeda M Neurosci Lett 513(2):
204-208, 2012
8 Relationship of prepulse inhibition to temperament and character in healthy Japanese subjects Takahashi H, Iwase M, Yasuda Y, Ohi K, Fukumoto M, Iike N, Yamamori H, Nakahachi T, Ikezawa K, Azechi M, Canuet L, Ishii R, Kazui H, Hashimoto R, Takeda M Neurosci Res 72(2):
187-193, 2012
9 Impact of the Genome Wide Supported NRGN Gene on Anterior Cingulate Morphology in Schizophrenia Ohi K, Hashimoto R, Yasuda Y, Nemoto K, Ohnishi T, Fukumoto M, Yamamori H, Umeda-Yano S. Okada T, Iwase M, Kazui H, Takeda M PLoS One 7(1):e29780,
2012
10 The p250GAP Gene is Associated with Risk for Schizophrenia and Schizotypal Personality Traits Ohi K, Hashimoto R, Nakazawa T, Okada T, Yasuda Y, Yamamori H, Fukumoto M, Umeda-Yano S, Iwase M, Kazui H, Yamamoto T, Kano M, Takeda M PLoS One  7(4):e35696,
2012
11 Common Variants in MAGI2 Gene Are Associated with Increased Risk for Cognitive Impairment in Schizophrenic Patients Koide T, Banno M, Aleksic B, Yamashita S, Kikuchi T, Kohmura K, Adachi Y, Kawano N, Kushima I, Nakamura Y, Okada T, Ikeda M, Ohi K, Yasuda Y, Hashimoto R, Inada T, Ujiike H, Iidaka T, Suzuki M, Takeda M, Iwata N, Ozaki N PLos One 7(5):e36836,
2012
12 Discrimination of schizophrenic females from healthy women using multiple structural brain measures obtained with voxel-based morphometry Ota M. Sato N. Ishikawa M. Hori H. Sasayama D. Hattori K. Teraishi T. Obu S. Nakata Y. Nemoto K. Moriguchi Y. Hashimoto R. Kunugi H Psychiatry ClinNeurosci
66(7):611-7, 2012
13 Personality traits and schizophrenia: evidence from a case-control study and meta-analysis. Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Yamamori H, Iwase M, Kazui H, Takeda M Psychiatry Res  198(1):
7-11, 2012
14 Resequencing and Association Analysis of the KALRN and EPHB1 Genes And Their Contribution to Schizophrenia Susceptibility Kushima I, Nakamura Y, Aleksic B, Ikeda M, Ito Y, Shiino T, Okochi T, Fukuo Y, Ujike H, Suzuki M, Inada T, Hashimoto R, Takeda M, Kaibuchi K, Iwata N, Ozaki N Schizophr Bull 38(3):
552-560, 2012
15 Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D Schizophr Res 137(1-3):
246-50, 2012
16 A two-stage case-control association study between the tryptophan hydroxylase 2(TPH2) gene and schizophrenia in a Japanese population Watanabe Y, Egawa J, Iijima Y, Nunokawa A, Kaneko N, Shibuya M, Arinami T, Ujike H, Inada T, Iwata N, Tochigi M, Kunugi H, Itokawa Ma, Ozaki N, Hashimoto R, Someya T Schizophr Res, 137:
264-266, 2012
17 Meta-analysis of association studies between DISC1 missense variants and schizophrenia in Japanese population Kinoshita M, Numata S, Tajima A, Ohi K, Hashimoto R, Shimodera S, Imoto I, Itakura M, Takeda M, Ohmori T Schizophr Res 141(2-3):271-3, 2012
18 Expression analysis of a novel mRNA variant of the schizophrenia risk gene ZNF804A Okada T, Hashimoto R, Yamamori H, Umeda-Yano S, Yasuda Y, Ohi K, Fukumoto M, Ikemoto K, KUnii Y, Tomita H, Ito A, Takeda M Schizophr Res 141(2-3):
277-8, 2012
19 Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor Fujimoto M, Hayashi T, Urfer R, Mita S, Su TP  Synapse 66:630-639,
2012
20 The sigma-1 receptor: roles in neuronal plasticity and disease Kourrich S, Su TP, Fujimoto M, Bonci A Trends in Neurosciences
35(12):762-71, 2012
2011 1 Expression array of lymphoblasts from schizophrenic patients Yamamori H, Hashimoto R, Verral L, Yasuda Y, Ohi K, Fukumoto M, Ito A, Takeda M Asian J Psychiatr
(Abstracts of the 3rd
World Congress of Asian
Psyciatry), S10. 2011
2 Risk genes of cognitive impairment of schizophrenia Takeda M, Yamamori H, Hashimoto R Asian J Psychiatr
(Abstracts of the 3rd
World Congress of Asian
Psyciatry), S10. 2011
3 Genome-wide association study of schizophrenia in a Japanese population Ikeda M, Aleksic B, Kinoshita Y, Okochi T, Kawashima K, Kushima I, Ito Y, Nakamura Y, Kishi T, Okumura T, Fukuo Y, Williams HJ, Hamshere ML, Ivanov D, Inada T, Suzuki M, Hashimoto R, Ujike H, Takeda M, Craddock N, Kaibuchi K, Owen MJ, Ozaki N, O'Donovan MC, Iwata N Biol Psychiatry 69(5):
472-78, 2011
4 Prepulse inhibition of startle response: recent advances in human studies of psychiatric disease Takahashi H, Hashimoto R,  Iwase M, Ishii R, Kamio Y, Takeda M Clin Psychopharmacol
Neursoci 9, 102-10, 2011
5 PACAP is implicated in the stress axes Hashimoto H, Shintani N, Tanida M, Hayata A, Hashimoto R, Baba A Curr Pharm Des, review
17(10):985-9, 2011
6 Translational research for schizophrenia-genes Takeda M, Yasuda Y, Ohi K, Fukumoto M, Yamamori H, Hashimoto R Intermediate Phenotypes
and Neurobiology.
The 2nd Asian Congress on
Schizophrenia Research
,19, 2011.
7 Dysbindin-1 and NRG-1 gene expression in immortalized lymphocytes from patients with schizophrenia Yamamori H, Hashimoto R, Verrall L, Yasuda Y, Ohi K, Fukumoto M, Umeda-Yano S, Ito A, Takeda M J Hum Genet56(7):478-83,
2011
8 Gene expression analysis in lymphoblasts derived from patients with autism spectrum disorder Yasuda Y, Hashimoto R, Yamamori H, Ohi K, Fukumoto M, Umeda-Yano S, Mohri I, Ito A, Taniike M, Takeda M Molecular Autism 2:9,
2011
9 Variants of the RELA gene are associated with schizophrenia and their startle responses Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Yamamori H, Takahashi H, Iwase M, Okochi T, Kazui H, Saitoh O, Tatsumi M, Iwata N, Ozaki N, Kamijima K, Kunugi H, Takeda M Neuropsychopharmacology
36(9):1921-31, 2011
10 Impact on schizotypal personality trait of a genome-wide supported psychosis variant of the ZNF804A gene Yasuda Y, Hashimoto R, Ohi K , Fukumoto M, Umeda-Yano S, Yamamori H, Okochi T, Iwase M, Kazui H, Iwata N, Takeda M Neurosci let495:216-20,
2011
11 Reduced rate of neural differentiation in the dentate gyrus of adult dysbindin null (sandy) mouse Nihonmatsu-Kikuchi N, Hashimoto R, Hattori S, Matsuzaki S, Shinozaki T, Miura H, Ohota S, Tohyama M, Takeda M, Tatebayashi Y PLoS One18;6(1):e15886,
2011
12 Correlated alterations in serotonergic and dopaminergic modulations at the hippocampal mossy fiber synapse in mice lacking dysbindin Kobayashi K, Umeda-Yano S, Yamamori H, Takeda M, Suzuki H, Hashimoto R PLoS One23;6(3):e18113,
2011
13 The SIGMAR1 gene is associated with a risk of schizophrenia and activation of the prefrontal cortex Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Yamamori H, Umeda-Yano S, Kamino K, Ikezawa K, Azechi M, Iwase M, Kazui H, Kasai K, Takeda M Prog
Neuropsychopharmacol
Biol Psychiatry 35:
1309-15, 2011 
14 A polymorphism of the ABCA1 gene confers susceptibility to schizophrenia and related brain changes Ota M, Fujii T, Nemoto K, Tatsumi M, Moriguchi Y, Hashimoto R, Sato N, Iwata N, Kunugi H Prog
Neuropsychopharmacol
Biol　Psychiatry35(8):　1877-83, 2011
15 Pharmacogenomics of antipsychotics efficacy Cacabelos R, Hashimoto R, Takeda M Psychiatry Clin Neurosci
65: 3-19, 2011
16 No association between the PCM1 gene and schizophrenia: a multi-center case-control study and a meta-analysis Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Yamamori H, Kamino K, Morihara T, Iwase M, Kazui H, Numata S, Ikeda M, Ueno S, Ohmori T, Iwata N, Ozaki N, Takeda M Schizophrenia Res129:
80-84, 2011
17 Dysbindin and pathophysiology of schizophrenia Hashimoto R, Yasuda Y, Ohi K, Fukumoto M, Yamamori H, Takeda M The 2nd Asian Congress
on Schizophrenia
Research, 20, 2011
18 Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders Hayashi T, Tsai S, Mori T, Fujimoto M, Su T. EXPERT OPINION ON THERAPEUTIC TARGETS. 15(5) 557-577. 2011.05
19 NEW INSIGHTS INTO THE ROLE OF MITOCHONDRIA-ASSOCIATED ENDOPLASMIC RETICULUM MEMBRANE. Fujimoto M, Hayashi T. INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 292. 292 73-117. 2011
2010 1 Detergent-Resistant Microdomains Determine the Localization of sigma-1 Receptors to the Endoplasmic Reticulum-Mitochondria Junction Hayashi T, Fujimoto M. MOLECULAR PHARMACOLOGY. 77(4) 517-528, 2010.04
2008 1 Altered expression of neurotrophic factors in patients with major depression Otsuki K, Uchida S, Watanuki T, Wakabayashi Y, Fujimoto M, Matsubara T, Funato H, Watanabe Y. JOURNAL OF PSYCHIATRIC RESEARCH. 42(14) 1145-1153, 2008.10
2 State-dependent changes in the expression levels of NCAM-140 and L1 in the peripheral blood cells of bipolar disorders, but not in the major depressive disorders Wakabayashi Y, Uchida S, Funato H, Matsubara T, Watanuki T, Otsuki K, Fujimoto M, Nishida A, Watanabe Y. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY. 32(5) 1199-1205, 2008.07.01
3 Reduced expression of glyoxalase-1 mRNA in mood disorder patients Fujimoto M, Uchida S, Watanuki T, Wakabayashi Y, Otsuki K, Matsubara T, Suetsugi M, Funato H, Watanabe Y. NEUROSCIENCE LETTERS. 438(2) 196-199, 2008.06
4 Characterization of the vulnerability to repeated stress in Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of the glucocorticoid receptor. Uchida S, Nishida A, Hara K, Kamemoto T, Suetsugi M, Fujimoto M, Watanuki T, Wakabayashi Y, Otsuki K, McEwen B, Watanabe Y. EUROPEAN JOURNAL OF NEUROSCIENCE. 27(9) 2250-2261, 2008.05
5 Morphological alterations of hippocampal pyramidal neurons induced by chronic stress in F344 rats Fujimoto M, Uchida S, Hara K, Watanabe Y. PSYCHIATRY AND CLINICAL NEUROSCIENCES. 62(1) S8-S8. 2008.05
2007 1 Involvement of microRNA-mediated downregulation of glucocorticoid receptor in vulnerability to stress Uchida S, Nishida A, Hara K, Suetsugi M, Fujimoto M, Watanabe Y. NEUROSCIENCE RESEARCH. 58 S166-S166. 2007
2006 1  [The current status and objectives for psychiatric medicine in Chugoku and Shikoku areas: a view from affiliated medical organizations]. Suenaga K, Fujimoto M, Yoshioka T. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. 108(9) 966-972, 2006